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The Courage Trial: A Phase II Randomized Clinical Trial to Evaluate the DoseResponse Effects of Exercise on Prognostic Biomarkers Among Colon Cancer
Survivors
Abstract
Observational epidemiologic data suggest that participation in physical activity after a diagnosis of colon
cancer reduces the risk of cancer recurrence, cancer-specific mortality, and all-cause mortality. However,
the biologic mechanisms that mediate the relationship between physical activity and disease outcomes
among colon cancer survivors have not been characterized. Excess visceral adipose tissue and
hyperinsulinemia promote the growth and progression of existing micro-metastases and the development
of new distant metastases. Exercise reduces visceral adipose tissue and hyperinsulinemia among nondiabetic persons with obesity. However, it is unknown if exercise alters visceral adipose tissue and
hyperinsulinemia among colon cancer survivors. We conducted a phase II, randomized, six month, doseresponse exercise trial that compared 150 min•wk-1 or 300 min•wk-1 of moderate-intensity aerobic
exercise to a usual care control group among 39 colon cancer survivors. We examined the efficacy of
exercise to reduce visceral adipose tissue and fasting insulin. To understand the generalizability of this
trial we examined demographic, clinical, and geographic characteristics of trial participants as compared
to the cancer registry population from which they were recruited. Mean age was 56.5±10.0 years, 51% had
stage III disease, 72% were treated with chemotherapy, and the mean time since finishing treatment was
10.9±6.1 months. Over six months, the low-dose group completed 141.5±9.9 min∙wk-1 of aerobic
exercise, and the high-dose group completed 247.2±10.7 min∙wk-1 of aerobic exercise. VAT increased
5.31±4.80 cm2 in the control group, and decreased 4.13±4.53 in the low-dose group, and 8.27±4.89 in the
high-dose group (linear Ptrend=0.008). Fasting insulin concentrations decreased 7.4±9.4 pmol/L in the
control group, 28.0±8.3 pmol/L in the low-dose group, and 20.7±9.3 pmol/L in the high-dose group
(nonlinear Ptrend=0.042). Colon cancer survivors screened for eligibility and enrolled in the study were
younger (screening P<0.001, enrollment P=0.007) and more likely to have been treated with
chemotherapy (screening P<0.001, enrollment P=0.006) than the population from which they were
recruited. The findings from this trial inform key design aspects for future phase II and phase III
randomized controlled trials among colon cancer survivors.
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ABSTRACT
THE COURAGE TRIAL: A PHASE II RANDOMIZED CLINICAL TRIAL TO EVALUATE
THE DOSE-RESPONSE EFFECTS OF EXERCISE ON PROGNOSTIC BIOMARKERS
AMONG COLON CANCER SURVIVORS
Justin C. Brown
Kathryn H. Schmitz
Observational epidemiologic data suggest that participation in physical activity after a
diagnosis of colon cancer reduces the risk of cancer recurrence, cancer-specific
mortality, and all-cause mortality. However, the biologic mechanisms that mediate the
relationship between physical activity and disease outcomes among colon cancer
survivors have not been characterized. Excess visceral adipose tissue and
hyperinsulinemia promote the growth and progression of existing micro-metastases and
the development of new distant metastases. Exercise reduces visceral adipose tissue
and hyperinsulinemia among non-diabetic persons with obesity. However, it is unknown
if exercise alters visceral adipose tissue and hyperinsulinemia among colon cancer
survivors. We conducted a phase II, randomized, six month, dose-response exercise
trial that compared 150 min·wk-1 or 300 min·wk-1 of moderate-intensity aerobic exercise
to a usual care control group among 39 colon cancer survivors. We examined the
efficacy of exercise to reduce visceral adipose tissue and fasting insulin. To understand
the generalizability of this trial we examined demographic, clinical, and geographic
characteristics of trial participants as compared to the cancer registry population from
which they were recruited. Mean age was 56.5±10.0 years, 51% had stage III disease,
72% were treated with chemotherapy, and the mean time since finishing treatment was
10.9±6.1 months. Over six months, the low-dose group completed 141.5±9.9 min·wk-1 of
aerobic exercise, and the high-dose group completed 247.2±10.7 min·wk-1 of aerobic
vi

exercise. VAT increased 5.31±4.80 cm2 in the control group, and decreased 4.13±4.53
in the low-dose group, and 8.27±4.89 in the high-dose group (linear Ptrend=0.008).
Fasting insulin concentrations decreased 7.4±9.4 pmol/L in the control group, 28.0±8.3
pmol/L in the low-dose group, and 20.7±9.3 pmol/L in the high-dose group (nonlinear
Ptrend=0.042). Colon cancer survivors screened for eligibility and enrolled in the study
were younger (screening P<0.001, enrollment P=0.007) and more likely to have been
treated with chemotherapy (screening P<0.001, enrollment P=0.006) than the population
from which they were recruited. The findings from this trial inform key design aspects for
future phase II and phase III randomized controlled trials among colon cancer survivors.
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CHAPTER 1. INTRODUCTION
Prologue
Each year 83,000 people are diagnosed with stage I-III colon cancer in the United States
[Siegel et al, 2015]. Despite being cured of their primary cancer, 25-50% will experience
recurrent disease within three years of diagnosis, and 91% of those with recurrent
disease die within five years after their initial diagnosis [Sargent et al, 2005]. Colon
cancer survivors consistently cite fear of recurrent disease as their chief health concern
[Baker et al, 2005]. Consequently, physicians often field questions such as “Should I
exercise? Should I lose weight? What will improve my chances?” Unfortunately, colon
cancer survivors soon learn there are few definitive answers to such basic inquiries.
Understanding how modifiable lifestyle behaviors such as physical activity or exercise
may affect disease outcomes will advance the management of colon cancer and
empower patients with practical solutions to improve their outcomes.
Observational studies indicate that participation in physical activity or exercise after a
diagnosis of colon cancer is associated with a 50% reduction in the risk of cancer
recurrence and mortality [Meyerhardt et al, 2006, Meyerhardt et al, 2006]. Physical
activity is associated with improved disease outcomes in a dose-response fashion, such
that increasing volumes of physical activity are associated with more favorable outcomes
[Schmid and Leitzmann, 2014]. However, the biologic or biobehavioral pathways
through which physical activity or exercise may favorably alter disease outcomes among
colon cancer survivors have not been elucidated. Two pathways hypothesized to
mediate the relationship between exercise and disease outcomes among colon cancer
survivors include alterations in body composition and alterations in insulin metabolism
and glucose homeostasis. This study will help to clarify how exercise may alter
1

pathways hypothesized to influence disease outcomes and the sensitivity of such
pathways to respond to different doses of exercise. We will also examine the
generalizability of these findings to the broader population of colon cancer survivors.
The data gathered from this study will improve the specificity of exercise prescriptions
provided to colon cancer survivors, strengthen the rationale that a causal relationship
exists between exercise and disease outcomes, and help to refine key design aspects
for future randomized trials in this population.

Colon Cancer Treatment and Prognosis
Each year, 103,000 people are diagnosed with colon cancer in the United States [Siegel
et al, 2015]. Among those diagnosed, 39% will have stage I-II colon cancer (localized to
the primary site), 36% will have stage III colon cancer (spread to regional lymph nodes),
and 20% will have stage IV colon cancer (distant metastatic disease) [DeSantis et al,
2014, Siegel et al, 2014]. For patients with metastatic colon cancer, the five-year
survival rate is 10%. In contrast, five-year survival rates for stage I-II and stage III colon
cancer are 90% and 70%, respectively [DeSantis et al, 2014]. Surgery is the primary
treatment modality for stage I-III colon cancer, with a curative resection occurring in 80–
85% of patients. Adjuvant chemotherapy is used to lower the risk of recurrence in
patients with stage II disease who have high-risk features (such as T4 lesions,
inadequate lymph node resection, poorly differentiated histology, presence of
lymphovascular invasion, and bowel obstruction or perforation) and in patients with
stage III disease [André et al, 2004, Quasar Collaborative Group, 2007]. Despite
surgical resection, either alone or in combination with adjuvant chemotherapy, five-year
recurrence rates for stage I, II, and III colon cancer are 10%, 20%, and 30-50%,
respectively [André et al, 2004, Clinical Outcomes of Surgical Therapy Study Group,
2

2004, Quasar Collaborative Group, 2007]. Although many patients may be cured with
standard therapy, there remains a critical need to identify additional adjuvant therapies
to reduce recurrent disease in this population.

Colon Cancer Outcomes: Recurrence and Metastasis
The high rate of recurrent and metastatic disease is a critical barrier to the health and
longevity of colon cancer survivorship. Cancer recurrence and metastasis are the
leading causes of morbidity and mortality in colon cancer, marking the transition from
localized, potentially curable to disseminated, usually incurable disease [Renfro et al,
2015]. Colon cancer recurrence is often characterized by loco-regional relapse and/or
distant metastasis to the liver or lung [Tsikitis et al, 2009]. Eighty percent of recurrences
occur in the first three years after treatment, and 91% of those with recurrent disease die
within five years after their initial diagnosis [Sargent et al, 2005]. The timing and pattern
of colon cancer recurrence is consistent with the hypothesis that colon cancer survivors
have residual local and distant micro-metastases remaining at the completion of curative
therapy [Chambers et al, 2002, Meyerhardt et al, 2010], which cannot be identified using
contemporary surveillance methods such as computed tomography (CT) and serum
levels of carcinoembryonic antigen (CEA) [Primrose et al, 2014].
Interventions that attenuate host factors that are hypothesized to promote the
progression of these residual local and distant micro-metastases may improve long-term
outcomes among colon cancer survivors. Two such host factors include body
composition, specifically excess visceral adipose tissue (VAT), and metabolic factors,
specifically insulin [Schwartz and Yehuda-Shnaidman, 2014, Vigneri et al, 2015]. The
prevention of cancer recurrence and metastasis are key health priorities for colon cancer
survivors [Baker et al, 2005]. Developing interventions that colon cancer survivors can
3

accomplish autonomously, such as modification of lifestyle with exercise, will equip colon
cancer survivors with practical solutions to improve their outcomes.

Colon Cancer Outcomes and Visceral Adipose Tissue
The two main compartments in which adipose tissue are stored include: 1)
subcutaneous adipose tissue (SAT) and 2) VAT [Ibrahim, 2010]. SAT represents a
usual physiologic buffer to store excess energy. When the storage capacity of SAT is
exceeded, VAT is accrued. Accordingly, 80–90% of all body fat is SAT, and the
remaining 10–20% is VAT [Tchernof and Despres, 2013]. The adipocytes that constitute
VAT are physiologically and pathologically distinct from SAT [Ibrahim, 2010, Tchernof
and Despres, 2013]. The adipocytes of VAT are more deleterious to health than the
adipocytes of SAT, due to their metabolic secretion of bioactive compounds such as
adipokines, cytokines, hormone-like factors, and other metabolites [Ahima and Flier,
2000, Balistreri et al, 2010]. The deleterious metabolic activity of VAT, coupled with
anatomic proximity to vital organs, and direct drainage into portal venous vasculature (a
key route of many colon cancer metastases), manifests as a pro-tumorigenic milieu
(Figure 1.1) [Doyle et al, 2012].
Excess VAT independently predicts poor colon cancer outcomes. Seven observational
epidemiologic studies have examined the relationship between VAT and colon cancer
outcomes. Five studies have quantified VAT using CT imaging [Ballian et al, 2012, Guiu
et al, 2010, Lee et al, 2015, Moon et al, 2008, Rickles et al, 2013], and two studies have
quantified VAT using waist circumference as an anthropometric proxy [Haydon et al,
2006a, Prizment et al, 2010]. All seven of these studies concluded that higher levels of
VAT are associated with poorer colon cancer outcomes such as disease-free survival,
cancer-specific mortality, and all-cause mortality. For example, among 62 colon cancer
4

survivors, above-median values of VAT were associated with four-fold increase in the
risk of disease recurrence or mortality over five years [Lee et al, 2015]. Among 526
colon cancer survivors, each 10-centimeter increase in waist circumference is
associated with a 20% increase in the risk of colon cancer-specific mortality [Haydon et
al, 2006a]. In addition, excess VAT is a strong independent predictor of all-cause
mortality among older adults without a history of cancer. Among 1,089 men and women
aged 18–84, each 70.1 cm2 (standard deviation) increase in VAT was associated with a
74% increase in the risk of all-cause mortality, independent of age, smoking status, and
cardiovascular disease [Katzmarzyk et al, 2012]. The relationship between VAT and
mortality is j-shaped, such that as VAT increases, the risk of mortality increases
exponentially [Kuk et al, 2006].
Body mass index (BMI), defined as weight (in kilograms) divided by height (in meters)
squared (kg/m2), is a widely used metric to quantify body composition. Elevated BMI is
associated with the development of incident colon cancer [Larsson and Wolk, 2007],
however several studies have concluded that BMI does not consistently influence colon
cancer outcomes after diagnosis [Vrieling and Kampman, 2010]. For example, among
1,053 stage III colon cancer survivors, greater BMI at diagnosis was not associated with
recurrence (Ptrend=0.86), disease-free survival (Ptrend=0.65), or all-cause mortality
(Ptrend=0.63) [Meyerhardt et al, 2008]. These findings are in contrast to the consistent
deleterious impact of VAT on colon cancer outcomes, as described above. BMI and
VAT are poorly correlated [Ballian et al, 2012]; for example, a patient may have a normal
weight BMI, but have pathogenic levels of VAT, or vice-versa (Figure 1.2). BMI as a
measure of adiposity assumes that fat tissue is distributed uniformly across the body,
ignoring the known heterogeneity of regional deposition of adiposity [Tchernof and
5

Despres, 2013]. There exists substantial inter-individual variation between BMI and
VAT. For example at a given BMI (30.0 kg/m2), VAT may vary by as much as 40%
[Després, 2011]. Among colon cancer survivors, BMI accounts for only 30.4% of the
variability in VAT [Rickles et al, 2013]. Thus, the location of adiposity may be more
influential on colon cancer outcomes than the quantity of total-body adiposity (i.e, VAT
may be a better marker of recurrence risk than BMI). Together, these observations
support that hypothesis that VAT is a metabolically active tissue that lends rise to
deleterious colon cancer outcomes [Doyle et al, 2012]. VAT is associated with insulin
resistance and resultant hyperinsulinemia among colon cancer survivors (r=0.519;
P<0.001) [Jiang et al, 2014], which is implicated in the progression of recurrent and
metastatic colon cancer [Vigneri et al, 2015].

Colon Cancer Outcomes and Hyperinsulinemia
Hyperinsulinemia is characterized by an elevated concentration of insulin and
exaggerated insulin response to increases in glucose concentration [Shanik et al, 2008].
The adipocytes of VAT are more insulin-resistant than the adipocytes of SAT [Ibrahim,
2010]. VAT is positively associated with fasting insulin [Seidell et al, 1990], and
accounts for 18–40% of the variability in fasting insulin [Colman et al, 1995]. Each 10cm2 increase in VAT area is associated with a 0.46 μU/mL increase in fasting insulin
[Goodpaster et al, 2003]. VAT is an independent predictor of insulin sensitivity, a
measure of how efficiently insulin acts to lower blood glucose [Racette et al, 2006]. The
relationship between VAT and insulin is important because colon cancer cells have
insulin and insulin-like growth factor-I (IGF-I) receptors on their surface [Belfiore and
Malaguarnera, 2011]. Insulin and IGF-I promote colon cancer cell proliferation and
inhibit apoptosis [Koenuma et al, 1989], thereby increasing the aggressiveness of the
6

tumor phenotype [Vigneri et al, 2015]. In vitro studies demonstrate the state of
hyperinsulinemia increases colon cancer cell resistance to 5-fluorouracil [Chen et al,
2011b] and oxaliplatin chemotherapy [Chen et al, 2011a, Volkova et al, 2014].
Preclinical models demonstrate that exposure to insulin promotes colonic tumor
multiplicity [Tran et al, 1996].
Colon cancer survivors have fasting insulin levels that are 58% higher than age- and
sex-matched controls without a history of colon cancer [Jiang et al, 2014].
Hyperinsulinemia is often observed among people diagnosed with early stage type 2
diabetes mellitus (T2DM). Colon cancer survivors with T2DM have significantly worse
prognosis than those without T2DM [Dehal et al, 2012, Jeon et al, 2013, Luo et al, 2014,
Meyerhardt et al, 2003]. For example, among 3,759 stage II/III colon cancer survivors,
those with T2DM had shorter five-year disease-free survival (48% vs. 59%), and shorter
five-year overall survival (57% vs 66%) [Meyerhardt et al, 2003]. Markers of insulin
secretion, such as C-peptide, are associated with a two-fold increase in the risk of death
among men and women diagnosed with colon cancer [Wolpin et al, 2009].
Hyperinsulinemia also promotes IGF-I biosynthesis, which inhibits production of insulinlike growth factor binding protein (IGFBP)-3 [Sandhu et al, 2002]. Low levels of IGFBP-3
are associated with a higher risk of death among non-metastatic colon cancer survivors
[Haydon et al, 2006b, Wolpin et al, 2009]. Together, this evidence which spans from in
vivo models to human observational studies, supports the hypothesis that
hyperinsulinemia is associated with recurrence and metastasis among colon cancer
survivors. The relationship between VAT and hyperinsulinemia yields a pro-tumorigenic
environment which may facilitate the progression of recurrent and metastatic disease
among colon cancer survivors [Doyle et al, 2012]. Interventions that reduce VAT and/or
7

reduce hyperinsulinemia/insulin resistance may therefore have considerable impact on
understanding colon cancer biology and improving the longevity of colon cancer
survivorship.

Mechanisms of VAT and Insulin Relevant to Colon Cancer Outcomes
Though not completely elucidated, the PI3K-Akt-mTOR signaling pathway is a point of
convergence that links both excess VAT and hyperinsulinemia to poor colon cancer
outcomes [Huang and Chen, 2009, Weijenberg et al, 2013]. The PI3K-Akt-mTOR
pathway is often hyper-activated in colon cancer [Wang and Zhang, 2014], and inhibition
of this pathway has been considered a therapeutic target [Huang and Chen, 2009].
mTOR is activated by Akt, inhibited by AMPK, and the activation of mTOR regulates cell
survival, proliferation, and growth. mTOR expression in colonic tumor tissue increases
with disease stage, lymph node metastasis, and lymphovascular invasion [AlQurashi et
al, 2013]. Activation of the PI3K-Akt-mTOR pathway is associated with the growth and
progression of colon cancer metastases [Gulhati et al, 2011]. Patients whose tumors
express mTOR tend to have lower median survival rates than patients whose tumors do
not express mTOR (43 v 60 months, respectively; P=0.06) [AlQurashi et al, 2013].
mTOR is sensitive to signals that reflect the nutritional and energetic states of the
cellular environment. In cellular environments with energy surplus, such as that with
excess VAT, hyperinsulinemia, and IGF-1, mTOR is activated via PI3K-Akt signaling
[McCurdy and Klemm, 2013]. This activation creates a competitive growth advantage
for cancer cells, and promotes metastatic potential and chemotherapy resistance [Porta
et al, 2014]. Conversely, in states of energy depletion, such as that required for
exercise, mTOR is inhibited via AMPK [Chen et al, 2003]. Favorably altering the
energetic states of the cellular environment by reducing excess VAT, hyperinsulinemia,
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and IGF-1 may down-regulate the PI3K-Akt-mTOR pathway. In a preclinical model,
silencing of mTOR inhibited the growth of colon cancer metastases and induced cellcycle arrest and apoptosis [Zhang et al, 2009]. Considerable evidence has accumulated
that implicates the PI3K-Akt-mTOR pathway in mediating the effects of excess VAT and
hyperinsulinemia on colon cancer outcomes [Huang and Chen, 2009, Weijenberg et al,
2013].

Colon Cancer Outcomes and Exercise or Physical Activity
Physical activity or exercise is a modifiable lifestyle behavior that is associated with
disease outcomes among colon cancer survivors. Among 832 stage III colon cancer
survivors, participation in physical activity after diagnosis was associated with a 45%
improvement in disease-free survival (defined as cancer recurrence or death from any
cause), and a 63% improvement in overall mortality [Meyerhardt et al, 2006]. This
observation has been replicated in multiple cohorts of men [Campbell et al, 2013,
Meyerhardt et al, 2009] and women [Campbell et al, 2013, Kuiper et al, 2012,
Meyerhardt et al, 2006], and is independent of known demographic, clinico-pathologic,
and treatment-related prognostic factors [Campbell et al, 2013, Kuiper et al, 2012,
Meyerhardt et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009].
A consistent finding in all of these cohort studies is that post-diagnosis physical activity is
associated with disease outcomes in a dose-response fashion, such that larger doses of
physical activity or exercise, up to approximately 300 minutes per week (min·wk-1), are
associated with more favorable disease outcomes [Campbell et al, 2013, Kuiper et al,
2012, Meyerhardt et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009]. The
relationship between physical activity volume and colon cancer outcomes has been
depicted as a linear or quadratic pattern using spline models (Figure 1.3) [Meyerhardt et
9

al, 2006, Meyerhardt et al, 2009]. The splines suggest 225 min·wk-1 may be the
minimum threshold necessary to improve colon cancer outcomes, however, outcomes
continue to improve beyond 225 min·wk-1, suggesting that larger doses up to 300
min·wk-1 may provide favorable disease-specific health benefits to colon cancer
survivors. This dose-response pattern has been confirmed in several meta-analyses
[Des Guetz et al, 2013, Je et al, 2013, Schmid and Leitzmann, 2014]. However, the
dose-response effects of exercise have not been studied among colon cancer survivors.
Interestingly, levels of physical activity before diagnosis of colon cancer are not
associated with colon cancer-specific mortality [Haydon et al, 2006a, Kuiper et al, 2012,
Meyerhardt et al, 2006, Pelser et al, 2014]. This suggests the biologic or biobehavioral
pathways through which physical activity reduces the primary development of colon
cancer may differ from that of the prevention of recurrence and metastases, yielding
greater focus upon the pro-tumorigenic milieu created by excess VAT and
hyperinsulinemia [Doyle et al, 2012, Quadrilatero and Hoffman-Goetz, 2003, Vigneri et
al, 2015]. The importance of the PI3K-Akt-mTOR pathway (as described earlier) is
supported by observations that examine the impact of molecular marker expression as
modifiers of the relationship between physical activity and colon cancer-specific death.
Among colon cancer survivors whose tumor is PI3KCA wild-type, participation in
physical activity is associated with a lower risk of colon cancer-specific death, whereas
colon cancer survivors whose tumor harbors a PI3KCA mutation do not reap any cancer
specific-survival benefit from physical activity [Meyerhardt et al, 2009]. The PI3KCA
mutation allows the PI3K-Akt-mTOR pathway to signal without regulation from the
cellular environment. Consequently, altering states of energy balance (via exercise or
other interventions) do not influence cell survival, proliferation, and growth. Furthermore,
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the PI3K-Akt-mTOR pathway regulates p27 expression, a cyclin-dependent kinase
inhibitor that controls cell cycle progression. Among colon cancer survivors whose
tumors express p27, participation in physical activity is associated with a lower risk of
colon cancer-specific death, whereas colon cancer survivors whose tumors do not
express p27 do not reap benefit from physical activity [Meyerhardt et al, 2009].
Together, these data provide further evidence that suggest the PI3K-Akt-mTOR pathway
may have an important intercellular role in mediating the impact of excess VAT and
hyperinsulinemia on colon cancer outcomes.
The American College of Sports Medicine (ACSM), the American Cancer Society (ACS),
and the National Comprehensive Cancer Network (NNCN) guidelines for cancer
survivors recommend 150 min·wk-1 of moderate-intensity physical activity [National
Comprehensive Cancer network, 2013, Rock et al, 2012, Schmitz et al, 2010]. This
recommendation is inconsistent with the dose of physical activity necessary to improve
disease outcomes in colon cancer survivors, as suggested by the epidemiologic
literature. Several reviews, including the ACSM statement for exercise among cancer
survivors, have called for more research to empirically investigate the dose-response
effects of exercise among cancer survivors [Brown et al, 2012b, Schmitz et al, 2010].

Exercise and Visceral Adipose Tissue
Exercise is an efficacious modality to reduce excess VAT. The “Studies of a Targeted
Risk Reduction Intervention through Defined Exercise” (STRRIDE) trial [Kraus et al,
2001], established the dose-response effects of exercise on VAT [Slentz et al, 2005,
Slentz et al, 2004]. The STRRIDE study was a four-arm randomized controlled trial that
compared three-doses of exercise to a control group for six months among 330 men and
women who were overweight or obese with mild to moderate lipid abnormalities [Kraus
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et al, 2001]. The STRRIDE study demonstrated a significant dose-response reduction in
VAT, quantified using computed tomography (Ptrend<0.001; Figure 1.4) and waist
circumference (Ptrend<0.001) [Slentz et al, 2005, Slentz et al, 2009, Slentz et al, 2004].
The dose-response effects of exercise on VAT have been replicated among adults with
the metabolic syndrome [Dutheil et al, 2013], and in meta-analyses of randomized
exercise trial using weighted regression models [Ohkawara et al, 2007, Vissers et al,
2013]. However, no study has examined the dose-response effects of exercise on VAT
among colon cancer survivors.

Exercise and Hyperinsulinemia
Exercise significantly reduces fasting insulin levels in dose-response fashion
[Friedenreich et al, 2011, Heydari et al, 2012, Houmard et al, 2004]. The STRRIDE
study demonstrated a significant reduction in fasting insulin (P<0.001), and significant
improvement in insulin sensitivity quantified using an intravenous glucose tolerance test
(P<0.05) [Houmard et al, 2004]. These findings have been corroborated in a post-hoc
analysis of a two-group randomized exercise study among overweight or obese postmenopausal women [Friedenreich et al, 2011]. Exercise-induced improvements in VAT
are associated with reductions in insulin resistance [O'Leary et al, 2006, Slentz et al,
2005].

Characterizing Eligibility Screening and Enrollment of Clinical Trials
Randomized clinical trials (RCTs) are considered the gold-standard study design to
quantify the efficacy of an intervention [Piantadosi, 2005]. Validity is commonly cited as
the primary reason why RCTs are the gold standard study design. There are two forms
of validity: internal validity and external validity. Internal validity relates to whether the
comparison of treatments is likely to be unbiased and un-confounded by external factors.
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External validity, also known as generalizability, relates to whether the study results can
be extended to the majority of patients for whom the results of the study may apply.
RCTs are frequently designed in such a way that maximizes internal validity,
subsequently reducing external validity [Gross et al, 2002, Wright et al, 2006]. Lack of
external validity is a frequent criticism of RCTs, because patients enrolled in RCTs may
differ from the general patient population with respect to demographic, clinical, and
geographical characteristics such as age, sex, race, disease stage, and place of
residence [Rothwell, 2005, Unger et al, 2014]. The enrollment process of RCTs has
been presented in a conceptual framework by Gross et al. in “who are these patients
and how did they get here?” [Gross et al, 2002]. This conceptual framework depicts flow
of potential study participants through three distinct stages of recruitment (Figure 1.5).
In stage one, investigators approach persons who are thought to represent a random
sample of the underlying target population. In stage two, persons who are approached
and interested in participating in the RCT are screened to determine eligibility. In stage
three, persons who are interested in participating and are determined to be eligible are
offered an opportunity to enroll in the RCT. In each of these distinct stages of RCT
enrollment, it is plausible that persons who proceed to the next stage represent a distinct
subset of the population from which they were sampled (i.e., the target population). For
example, persons screened in stage two may differ demographically, clinically, or
geographically, relative to persons identified in stage one [Rothwell, 2005]. Furthermore,
persons enrolled in stage three, may also differ demographically, clinically, or
geographically, compared to persons identified in stage one [Rothwell, 2005].
Systematic differences in characteristics among persons in each of these stages may
lead to selection bias that reduces the representativeness of RCT participants from the
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underlying target population. This lack of representativeness consequently reduces the
external validity of the RCT.
Lack of external validity in RCTs is hypothesized to partially explain the underuse of
efficacious interventions in clinical practice despite recommendations for their use in
clinical practice guidelines [Rothwell, 2005]. For example, the ACSM, ACS, and NCCN
recommend that healthcare providers prescribe exercise to all colon cancer survivors
[National Comprehensive Cancer network, 2013, Rock et al, 2012, Schmitz et al, 2010].
However only 16.3% of colon cancer survivors are prescribed exercise by their
healthcare provider, compared to 26.9% of matched adults without a history of cancer
(P=0.003) [Sabatino et al, 2007]. Survivors of breast, prostate, cervical, and uterine
cancer are prescribed exercise by their healthcare provider at rates similar to matched
adults without a history of cancer. These data indicate that healthcare providers may be
particularly reluctant to prescribe exercise to colon cancer survivors [Brown and Schmitz,
2014a].
To promote the prescription of exercise to colon cancer survivors in clinical practice,
RCTs of exercise need to systematically characterize how colon cancer survivors who
participate in an exercise RCT differ from those who do not participate. To date, few
exercise RCTs have characterized these differences. Characterizing these differences
would fill an evidence gap that may begin to solve several problems for healthcare
providers who are being asked to prescribe exercise and study investigators who are
generating data to support the prescription of exercise. First, healthcare providers would
have evidence to understand how colon cancer survivors who participate in an exercise
RCT may differ from patients who receive care in their clinical practice. Second, study
investigators would be able to identify colon cancer survivor subgroups that may be less
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likely to participate in an exercise RCT. These subgroups can subsequently become the
focus of targeted and tailored recruitment efforts to improve RCT participation and
generalizability. Characterizing how RCT participants differ from the population will also
provide investigators evidence to empirically describe the generalizability of their trial.
Filling this evidence gap may help to promote exercise as a standard component of
colon cancer care and improve clinical trial methodology among colon cancer survivors
[Brown and Schmitz, 2014a].

Study Design
Together, this evidence formed the basis for the COURAGE trial. The COURAGE trial was a
National Cancer Institute (NCI) sponsored, phase II, randomized, dose-response
exercise trial of two distinct doses of moderate-intensity aerobic exercise compared to a
usual-care control group among non-metastatic colon cancer survivors.

Primary Research Questions & Hypotheses
The primary research questions and hypotheses addressed by the COURAGE trial in this
dissertation were as follows:
Specific Aim 1: To quantity and describe the dose-response effects of
moderate-intensity aerobic exercise on VAT, measured with a novel and
validated method using dual energy x-ray absorptiometry.
Hypothesis: We hypothesized that exercise will favorably reduce VAT in doseresponse fashion.
Specific Aim 2: To quantify and describe the dose-response effects of
moderate-intensity aerobic exercise on levels of fasting insulin.
15

Hypothesis: We hypothesized that exercise will favorably reduce levels of
fasting insulin in dose-response fashion.
Specific Aim 3: To quantify and describe demographic, clinical, and
geographical characteristics that associate with eligibility screening and study
enrollment in the COURAGE trial.
Hypothesis: We hypothesized that demographic, clinical, and geographical
characteristics will be associated with eligibility screening and study enrollment.

Placing the Courage Trial into Larger and Longer-Term Context
Exercise has potential pharmacologic properties that are similar to many drugs [Vina et
al, 2012]. Exercise and drug interventions are similar in terms of their mortality benefits
in the secondary prevention of coronary heart disease, rehabilitation after stroke,
treatment of heart failure, and the prevention of diabetes [Naci and Ioannidis, 2013].
The developmental pipeline for bringing exercise to the standard of clinical care for
adjuvant colon cancer should progress through a similar pipeline to that of drug
development. Because exercise is a complex and multifaceted behavior, the level of
preliminary evidence required to undertake a definitive phase III randomized controlled
trial should be abundant and consistently demonstrate the safety, feasibility, and
physiologic alterations that support the hypothesis of a causal relationship. We have
proposed a sequential phased process that systematically evaluates the critical
questions that should be answered prior to undertaking a phase III trial in this area
(Figure 1.6). At each sequential phase the physiologic specificity of the potential
benefits of exercise on disease outcomes is deepened. First, as with a drug, the
feasibility and safety of various exercise doses must be established. Second, we aim to
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understand how biomarkers representing various physiologic pathways respond to an
exercise stimulus. Such biomarkers may include VAT (adiposity), insulin (metabolic), Creactive protein (inflammation), or soluble intercellular adhesion molecules (endothelial
axis). The COURAGE trial will address these two phases. Subsequent to the COURAGE
trial, it will be necessary to examine how specific pathways (i.e., PI3K-Akt-mTOR)
change in response to exercise and how this may affect metastatic potential. Assuming
these hypotheses are supported, smaller multisite trials can be undertaken to
demonstrate the ability to coordinate and concentrate research efforts. After a
successful multi-site feasibility study, a definitive phase III trial with a clinical endpoint
can be initiated. This process is likely to be iterative as new questions and unanticipated
logistical, methodological, and scientific barriers arise. This proposed human
developmental pipeline should be supplemented with ongoing preclinical studies. This
proposed human developmental pipeline will systematically generate high quality data
that will help to inform the standard of clinical care for adjuvant colon cancer.

Summary
The propensity to recur is a formidable reality for colon cancer survivors and presents a
critical barrier to promote long term survivorship. Excess VAT and hyperinsulinemia are
hypothesized as important host factors that may promote colon cancer recurrence and
metastasis. Exercise has emerged as an adjuvant intervention that may confer
recurrence and survival benefits for people with colon cancer. However, the underlying
biologic or biobehavioral pathways that mediate the relationship between exercise and
colon cancer outcomes remain unidentified. It is plausible that exercise reduces VAT
and/or insulin levels, thereby reducing the pro-tumorigenic milieu, and minimizing the
growth and progression of residual local and distant micro-metastases. The preliminary
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data supporting these associations are strong, consistent with biologic plausibility, occur
in dose-response fashion, and have select aspects that are supported with randomized
data. Interventions to decrease VAT and/or fasting insulin among colon cancer survivors
will help to clarify how exercise may alter pathways that are hypothesized to influence
disease outcomes and the sensitivity of such pathways to respond to different doses of
exercise. Such data will improve the specificity of exercise prescriptions provided to
colon cancer survivors and strengthen the hypothesis of a causal relationship between
exercise and disease outcomes. In addition, the data from this dissertation will help to
refine key trial design characteristics for future randomized controlled trials in this area.
The long-term goal of this line of research is to generate definitive answers to the
questions “Should I exercise? Should I lose weight? What will improve my chances?”
that are asked by the 83,000 men and women who will be told “you have colon cancer”
each year. Seven in ten colon cancer survivors cite fear of disease recurrence as their
principal health concern [Baker et al, 2005]. Thoughts about recurrence are intrusive,
physically and psychologically debilitating, and alter long-term family and financial
planning [Simard et al, 2013]. These patients deserve to know how the choices they
make to purposefully alter lifestyle behaviors may influence their disease outcomes.
This information will empower patients, families, and providers with practical solutions to
improve outcomes.
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Figure 1.1 Mechanistic pathway describing how visceral adipose tissue promotes a protumorigenic environment. Adapted from [Doyle et al, 2012].
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Figure 1.2 Illustration of differences in body mass index (BMI) and visceral adipose
tissue among colorectal cancer patients using computed tomography at the level of the
umbilicus.
Red shading indicates visceral adipose tissue area (VFA). Blue shading indicates
subcutaneous tissue area (SFA). Patient ‘a’ has a BMI of 24.0 kg/m2 with a VFA/SFA of
1.49. Patient ‘b’ has a BMI of 48.0 kg/m2 and a VFA/SFA ratio of 0.35. Adapted from
[Ballian et al, 2012].
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Figure 1.3 Smoothing spline plot of disease-free survival and hours per week of walking.
Thick solid line represents that hazard ratio and dashed lines represent the 95%
confidence intervals. Adapted from [Meyerhardt et al, 2006].
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Figure 1.4 Relationship between amount of exercise per week and percent visceral fat
change. Adapted from [Slentz et al, 2009].
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Figure 1.5 The trial enrollment process: “who are these patients and how did they get
here?” Adapted from [Gross et al, 2002].
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Figure 1.6 Sequential phases of developing randomized controlled trials to examine the
relationship between exercise and disease outcomes in colon cancer. Adapted from
[Campbell et al, 2000].
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Abstract
Background: Observational studies indicate that higher volumes of physical activity are
associated with improved disease outcomes among colon cancer survivors. The aim of
this report is to describe the purpose, study design, methods, and recruitment results of
the COURAGE trial, a National Cancer Institute (NCI) sponsored, phase II, randomized,
dose-response exercise trial among colon cancer survivors.
Methods/Results: The primary objective of the COURAGE trial is to quantify the
feasibility, safety, and physiologic effects of low-dose (150 min·wk-1) and high-dose (300
min·wk-1) moderate-intensity aerobic exercise compared to usual-care control group over
six months. The exercise groups are provided with in-home treadmills and heart rate
monitors. Between January and July 2015, 1,433 letters were mailed using a
population-based state cancer registry; 126 colon cancer survivors inquired about
participation, and 39 were randomized onto the study protocol. Age was associated with
inquiry about study participation (P<0.001) and randomization onto the study protocol
(P<0.001). No other demographic, clinical, or geographic characteristics were
associated with study inquiry or randomization. The final trial participant was
randomized in August 2015. Six month endpoint data collection was completed in
February 2016.
Discussion: The recruitment of colon cancer survivors into an exercise trial is feasible.
The findings from this trial will inform key design aspects for future phase 2 and phase 3
randomized controlled trials to examine the efficacy of exercise to improve clinical
outcomes among colon cancer survivors.
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Introduction
There are 103,000 people diagnosed annually with colon cancer in the United States
[Siegel et al, 2014]. Among those diagnosed, 39% will have localized colon cancer
(confined to the primary site; stage I-II), 36% will have regional colon cancer (spread to
regional lymph nodes; stage III), and 20% will have metastatic disease (spread to distant
organs; stage IV) [DeSantis et al, 2014, Siegel et al, 2014]. Among those without
metastatic disease, five year survival rates for localized and regional colon cancer are
90% and 70%, respectively [Siegel et al, 2014]. Surgery is the primary treatment
modality for localized and regional colon cancer, with curative resection occurring in 8085% of patients [Clinical Outcomes of Surgical Therapy Study Group, 2004, Lacy et al,
2002]. Those with regional disease may also receive adjuvant chemotherapy to reduce
the risk of recurrent disease [Meyerhardt and Mayer, 2005]. Despite the efficacy of
surgical resection and adjuvant chemotherapy, 20-50% of patients with localized and
regional colon cancer develop recurrent disease [André et al, 2004, Quasar
Collaborative Group, 2007]. Eighty percent of recurrences occur within the first three
years after treatment, and 91% of patients who develop a recurrence by three years, die
before five years [Sargent et al, 2005]. Consequently, there exists a need to identify
additional adjuvant therapies that can be prescribed at the conclusion of standard colon
cancer therapy (e.g., surgery and chemotherapy) to minimize the risk of recurrence.
Such adjuvant therapies may include the modification of lifestyle behaviors.
Physical activity or exercise is a modifiable lifestyle behavior that is associated with
disease outcomes among colon cancer survivors. Among 832 stage III colon cancer
survivors, participation in approximately 300 min·wk-1 (18 to 27 MET-hours) of physical
activity after diagnosis was associated with a 45-49% improvement in disease-free
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survival (defined as cancer recurrence or death from any cause), and a 29-63%
improvement in overall mortality [Meyerhardt et al, 2006]. This observation has been
replicated in multiple cohorts of men [Campbell et al, 2013, Meyerhardt et al, 2009] and
women [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006], and is
independent of known demographic, clinico-pathologic, and treatment-related prognostic
factors [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006, Meyerhardt et
al, 2006, Meyerhardt et al, 2009]. A consistent finding in all of these cohort studies is
that post-diagnosis physical activity is associated with disease outcomes in a doseresponse fashion, such that larger doses of physical activity or exercise, up to
approximately 300 minutes per week (min·wk-1), is associated with more favorable
disease outcomes [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006,
Meyerhardt et al, 2006, Meyerhardt et al, 2009]. This dose-response pattern has been
confirmed in several meta-analyses [Des Guetz et al, 2013, Je et al, 2013, Schmid and
Leitzmann, 2014]. However, it is unknown if doses of exercise as large as 300 min·wk-1
are behaviorally feasible and have tolerable safety profiles for colon cancer survivors
when compared to smaller doses of exercise, such as 150 min·wk-1 as is currently
recommended by the American Cancer Society [Rock et al, 2012], American College of
Sports Medicine [Schmitz et al, 2010], and the National Comprehensive Cancer Network
[National Comprehensive Cancer network, 2013]. Furthermore, the biological or
biobehavioral pathways through which exercise may impact disease outcomes among
colon cancer survivors are unknown. Evaluating potential biomarkers and/or mediators
involved in the anti-cancer effects of exercise and the sensitivity of such biomarkers
and/or mediators to respond to different doses of exercise will help to identify the optimal
dose of exercise to improve outcomes and guide clinical decisions and
recommendations.
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Aims of this Report
The aims of this report are two-fold. First, we describe the purpose, study design, and
methods of the COURAGE trial, a National Cancer Institute (NCI) sponsored, phase II,
randomized, dose-response exercise trial of two distinct doses of moderate-intensity
aerobic exercise compared to a usual-care control group among colon cancer survivors.
Second, we present recruitment results to describe what demographic, clinical, or
geographic characteristics are associated with inquiry about study participation and
randomization onto the study protocol. Identifying the characteristics associated with
inquiry about study participation and randomization onto the study protocol will provide
empirical evidence to describe trial generalizability to the broader population of colon
cancer survivors.

Study Objectives & Outcomes
The primary objective of the COURAGE trial is to quantify the feasibility, safety, and
physiologic effects of low-dose (150 min·wk-1) aerobic exercise, high-dose (300 min·wk-1)
aerobic exercise, or usual-care control, among non-metastatic colon cancer survivors
over six months (Figure 2.1). The primary outcomes include exercise adherence,
adverse events, soluble intercellular adhesion molecule-1 (sICAM-1) and soluble
vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers. Key secondary
outcomes include visceral adipose tissue (VAT), and fasting insulin. Exploratory
outcomes include the enumeration of circulating tumor cells (CTCs), functional status,
and patient-reported outcomes and quality of life measures.
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Methods
All study activities as described below were reviewed and approved by the University of
Pennsylvania Human Subjects Protection Programs. The trial was registered with
ClinicalTrials.gov as NCT02250053.
Eligibility Criteria
To balance the goals of recruiting a homogeneous study cohort with recruitment
feasibility we a priori implemented a phased recruitment strategy which systematically
broadened eligibility criteria in each successive phase of recruitment. In phase 1 (most
strict) the inclusion criteria were as follows: histologically-confirmed stage II-III colon
cancer; completed surgical resection and adjuvant chemotherapy ≤24 months before
entering the study; ≤120 min·wk-1 of self-reported moderate or vigorous intensity physical
activity using the Paffenbarger Physical Activity Questionnaire [Paffenbarger et al, 1993];
age ≥18 years; written physician approval; no additional surgery planned within the six
month intervention (including colostomy reversal); and the ability to walk unaided for six
minutes. In phase 2 (less restrictive) the inclusion criteria were broadened to increase
the baseline self-reported physical activity level from ≤120 min·wk-1 to <150 min·wk-1,
and expanded the time since completing surgical resection and adjuvant chemotherapy
from ≤24 months to ≤36 months. In phase 3 (least restrictive) the inclusion criteria were
broadened from histologically-confirmed stage II-III colon cancer to histologicallyconfirmed stage I-III colon cancer, and expanded the time since completing surgical
resection and adjuvant chemotherapy to any period.
During all phases of recruitment, the exclusion criteria were as follows: history of another
primary cancer (other than non-melanoma skin-cancer); evidence of metastatic colon
cancer; planning to receive any additional adjuvant chemotherapy or surgery (i.e.,
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ostomy reversal); pregnant or breast feeding; unable to provide baseline blood sample;
cardiac conditions, including the following: myocardial infarction or coronary
revascularization procedure within the past three months, uncontrolled hypertension,
defined as a systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥100 mm
Hg, high-risk or uncontrolled heart arrhythmias, clinically significant heart valve disease,
decompensated heart failure, or known aortic aneurysm; and any other condition which,
in the opinion of the investigator, may impede testing of the study hypothesis or make it
unsafe to engage in the exercise program.
Participant Recruitment
Potentially-eligible study participants were recruited through the Pennsylvania Cancer
Registry (PCR) [Pennsylvania Department of Health]. The PCR is a member of the
North American Association of Central Cancer Registries (NAACCR) that is responsible
for collecting information on all new cases of cancer diagnosed and/or treated in the
state of Pennsylvania (i.e., the PCR is population-based). The PCR has received Gold
Certification from the NAACCR for excellence in areas of completeness, quality, and
timeliness of cancer incidence reporting. Potentially-eligible study participants were
listed in the PCR with international classification of diseases for oncology third edition
(ICD-O-3) codes for colon cancer (C18.0, C18.2-C18.9). Cancer of the rectum (C20.9)
was not eligible for participation. To minimize anticipated concerns regarding travel
burden into the city of Philadelphia from surrounding suburbs, potentially-eligible
participants were recruited from Philadelphia County and four surrounding counties
(Bucks, Montgomery, Chester, and Delaware). Using an envelope with the University of
Pennsylvania School of Medicine logo, potentially-eligible participants were sent one
letter via postal mail that included an invitation to participate signed by the principal
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investigator, a one page flyer describing the study, the name and contact information
(email, telephone) of the study coordinator, and a brochure describing the PCR. The
one page flyer that described the study included statements that mentioned the provision
of an in-home treadmill and an individualized exercise program. Mailings were
completed in four successive waves as new incident data became available from the
PCR (January, March, May, and July). This recruitment approach has been used by our
research group in prior studies among breast cancer survivors [Rogerino et al, 2009].
Participant Screening
Screening was conducted via a telephone interview. The telephone interview included a
brief description of the study, systematically queried callers about each of the abovedescribed inclusion and exclusion criteria, and administered the physical activity
readiness questionnaire (PAR-Q) [Shephard, 1994]. The PAR-Q is a seven item
questionnaire that identifies signs of cardiovascular disease, orthopedic conditions, and
medications that could affect physiologic responses to an increase in physical activity.
The PAR-Q has excellent sensitivity (close to 100%) and specificity (80%) for detecting
medical contraindications to exercise [Shephard, 1994]. After screening, eligible
participants were invited to the University of Pennsylvania to meet with the study
coordinator for 30-45 minutes to discuss the goals, objectives, risks, and benefits of the
study in detail. At that time, written informed consent was obtained from eligible
participants wishing to enroll in the study.
Study Measures
After obtaining written informed consent, the study coordinator sent a physician approval
form to each of the participant’s physicians, which often included the primary care
physician, surgical and/or medical oncologist, and other appropriate internal medicine
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specialists (e.g., cardiologist for participants with pre-existing cardiac conditions). The
physician approval form included a brief description of the study, the results of the PARQ screening questionnaire, and a request that the physician review this information and
provide approval that they believe their patient is medically fit to participate in a
moderate-intensity aerobic exercise study. After obtaining written physician approval,
the study participant completed a clinic visit at the University of Pennsylvania Center for
Clinical and Translational Research Center. The specific measures of the clinic visit are
described in detail below. All measures described below are completed at baseline and
at six months (except clinical characteristics 4.4.1). All measures are conducted by staff
blinded to study group.
Clinical Characteristics
Tumor-related characteristics including date of diagnosis and treatment completion,
stage (American Joint Committee on Cancer, 7th edition [Edge et al, 2010]), primary
tumor location within the colon, depth of tumor invasion (T-stage), number of positive
resected lymph nodes (N-stage), grade of histologic differentiation, presence of
lymphovascular invasion, and adjuvant chemotherapy are abstracted from the PCR
database, medical record review, and from treatment summary reports obtained from the
providing physician. Comorbidities and current medication and supplement use are
obtained using the Chronic Disease Scale [Von Korff et al, 1992]. The above-described
variables that were extracted from the PCR database were utilized to examine how
demographic, clinical, or geographic characteristics were associated with inquiry about
study participation and randomization onto the study protocol.
Blood Sample
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A total of 50mL of blood is collected by a licensed phlebotomist. Blood is collected after
a minimum of six hours of fasting, which is verified prior to venipuncture. Blood samples
are processed using standardized laboratory procedures and aliquots of serum and
EDTA-preserved plasma are stored in -80°C freezers. In addition to the biomarker
assays described below, additional aliquot samples are stored for future exploratory
analyses.
sICAM-1 is analyzed using an R&D systems enzyme linked immunoabsorbent assay
[Adamopoulos et al, 2001, Craft et al, 2008]. The inter-assay coefficient of variation and
sensitivity are 5.4%, and 0.049-0.254 ng/mL, respectively. sVCAM-1 is analyzed using
an R&D systems enzyme linked immunoabsorbent assay [Adamopoulos et al, 2001,
Craft et al, 2008]. The inter-assay coefficient of variation and sensitivity are 7.7%, and
0.17-1.26ng/mL, respectively. Fasting insulin is analyzed with a radioimmunoassay
(Millipore). The inter-assay coefficient of variation is 6%, and sensitivity ranges from 2.0200.0 μU/mL. Fasting glucose is analyzed with immuno-nephelometry assay. The interassay coefficient of variation is 2%, and sensitivity ranges from 0.6-45.0mmol/L. The
measurement of glucose serves as a quality control to enable the attribution of elevated
fasting levels to insulin resistance, rather than latent type 2 diabetes or blood samples
that were collected in a non-fasting manner. The homeostatic model (HOMA) is
calculated to quantify insulin resistance [Wallace et al, 2004]. Other associated
metabolic biomarkers including glycated hemoglobin (HbA1c), insulin-like growth factor1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP3), and C-peptide are also
analyzed.
CTCs from venous blood are isolated using geometrically enhanced differential
immunocapture (GEDI) [Gleghorn et al, 2010]. GEDI is a microfluidic platform that
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utilizes antibody coated obstacles to capture rare cells within anticoagulated whole
blood. To capture CTCs, obstacles are coated with an antibody specific to epithelial celladhesion molecule (EpCAM), an epithelial cell-specific marker. After washes, captured
cells are stained with the nuclear marker DAPI and fluorescently labeled antibodies to
the leukocyte marker CD45 and the epithelial cell marker Pdx-1. Using fluorescence
microscopy, Pdx1+/DAPI+/CD45- EpCAM captured cells with intact cellular morphology
are counted as CTC’s by a blinded technician.
Anthropometric Measures
For all anthropometric measures participants wear study-provided medical scrubs (top
and trousers). Height is measured using a wall-mounted digital stadiometer without
shoes to the nearest 0.1 centimeter. Weight is measured using a calibrated digital scale
to the nearest 0.1 kilogram. Height and weight are used to calculate body mass index
(kg/m2). Waist and hip circumference are measured using a Gulick spring-loaded tape
measure to the nearest 0.1 centimeter. Sagittal abdominal diameter is measured using
an abdominal caliper (Holtain-Kahn) to the nearest 0.1 centimeter [Zamboni et al, 1998].
Body composition is measured using whole-body dual-energy x-ray absorptiometry
(DXA; Hologic Discovery; APEX v 13.4 software). DEXA is used to quantify VAT (cm2),
subcutaneous adipose tissue (cm2), total fat mass (kg), and lean mass (kg). DXAderived VAT correlates with computed tomography derived VAT (r=0.93; P<0.001)
[Micklesfield et al, 2012], and is reliable across a large weight spectrum [Bredella et al,
2013].
Cardiopulmonary & Functional Status
A resting electrocardiogram is completed to identify any clinically-significant cardiac
conduction abnormalities [i.e., 3rd degree heart block, uncontrolled arrhythmia, or ST35

segment depressions (>3 mm)] that may preclude participation in exercise. Functional
status is measured using the six minute walk test (6MWT), following the guidelines of
American Thoracic Society [ATS Committee on Proficiency Standards for Clinical
Pulmonary Function Laboratories, 2002]. The outcome of the 6MWT is the distance
walked in six minutes, recorded to the nearest meter. The 6MWT is reliable, and
correlated with physiologic impairments of strength and power of the lower extremities
[Guyatt et al, 1985]. The 6MWT is also used to identify persons who may develop signs
and symptoms of cardiac distress, such as chest pain or severe shortness of breath
during exertion, which may preclude participation in exercise.
Physical Activity
Physical activity is measured using both self-reported and objective measures. The
Paffenbarger Physical Activity Questionnaire queries activities including flights of stairs
climbed, blocks walked, and other leisure-time physical activities performed on a typical
day or week [Paffenbarger et al, 1993]. The outcome of the Paffenbarger Physical
Activity Questionnaire is the total energy expenditure associated with leisure-time
physical activity, quantified in multiples of resting energy expenditures (METs) using the
compendium of physical activities [Ainsworth et al, 2000]. The ActiGraph model GT3X+
accelerometer is worn for seven consecutive days. Participants are provided with a
diary to document accelerometer wear time. The ActiGraph is a valid and reliable
objective measure of ambulatory activity [Bassett et al, 2000]. The main outcomes
obtained from the ActiGraph accelerometer will be the number of minutes of moderateto-vigorous physical activity (≥3 METs) and activity-related energy expenditure (kcals),
calculated using validated cut-points appropriate for adults [Troiano et al, 2008].
Dietary Intake
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Dietary intake is measured using three day dietary records collected during two
weekdays and one weekend day [Luhrmann et al, 1999]. Food records are entered into
the Nutrition Data System for Research software (2009 version) by registered dietitians.
The resulting data includes 165 micro- and macronutrient variables. Daily caloric intake
is the primary covariate of interest to determine if any observed physiologic changes are
due to exercise or the result of concurrent dietary alterations.
Patient-Reported Outcomes & Quality of Life Measures
In addition to the above-described physiologic measures, participants complete
questionnaires relating to demographics, alcohol and smoking habits, and various selfreport questionnaires that are known to influence the quality of life of colon cancer
survivors [Committee on Cancer Survivorship: Institute of Medicine and national
Research Board, 2006, Harrington et al, 2010]. Overall quality of life is assessed using
the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) [Ward et al, 1999],
and the SF-36 [Ware and Sherbourne, 1992]. Pain is assessed using the Brief Pain
Index [Cleeland and Ryan, 1994]. Sleep quality is assessed using the Pittsburgh Sleep
Quality Index [Buysse et al, 1989]. Bowel function is assessed using the Assessment of
Bowel Function Questionnaire [Haddock et al, 2007]. Cancer-related fatigue is
assessed using the Brief Fatigue Inventory [Mendoza et al, 1999]. Concerns about
cancer recurrence are measured with the Fear of Cancer Recurrence Inventory [Simard
and Savard, 2009].
Safety & Adverse Events
Participants in all study groups are asked each week by the study coordinator to identify
any incident health events. All reported health events are graded in accordance with the
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [US Department
37

of Health and Human Services, 2009]. At the end of the study, all participants complete
a healthcare utilization and musculoskeletal injury questionnaire asking about any
healthcare encounters and injuries experienced while in the study that may have not
been previously reported [Brown et al, 2012a, Warren and Schmitz, 2009]. The data
safety monitoring plan for this study focuses on monitoring by the principal investigator,
along with prompt reporting of excessive adverse events and any serious adverse
events to the National Institutes of Health and the Institutional Review Board at the
University of Pennsylvania.
Randomization
After completion of baseline measurements, participants were stratified by stage of colon
cancer (I vs. II vs. III) and randomized in a 1:1:1 ratio to either the low-dose (150 min·wk1

) aerobic exercise group, the high-dose (300 min·wk-1) aerobic exercise group, or the

usual-care control group.
Treatment Plan
Participants randomized into the low-dose and high-dose exercise groups increase their
exercise to 150 min·wk-1 and 300 min·wk-1, respectively. Participants randomized into
the low-dose and high-dose exercise groups are provided with an in-home treadmill
(LifeSpan Fitness, TR1200i, Salt Lake City, UT). Treadmills are ordered for participants
on the day of randomization. Participants who were unable to accommodate a treadmill
in their home were provided with a one-year health club membership (or other
membership of similar monetary value) to a facility of the participants choosing. After
treadmill delivery and setup, participants meet with a certified clinical exercise
physiologist at the University of Pennsylvania to introduce the exercise prescription, and
familiarize the participant to use of the treadmill, the completion of exercise logs, use of
38

a heart rate monitor (described below), appropriate warm-up and cool-down, stretches,
and proper footwear for aerobic exercise. The exercise physiologist provides ongoing
behavioral support and monitoring of exercise adherence to the study protocol
throughout the duration of the study. Behavioral support is individualized to each
participant to include the benefits of exercise for colon cancer survivors, strategies to
integrate exercise into day-to-day activities, how to identify and overcome barriers to
exercise, recruiting friends and family members to provide support in reaching their
exercise goals, and how to set simple, measureable, attainable, realistic, and timely
(SMART) goals [Weinberg, 1994] to promote exercise self-efficacy and compliance
[Courneya et al, 2008]. The modes through which behavioral support is delivered are
tailored to participant preference to maximize effectiveness of communication and
include in-person sessions (as described below), complemented with weekly
telephone/text, or email contact. If participants have upcoming scheduled medical
procedures that may result in missed exercise (i.e., the day of a surveillance
colonoscopy) the participant works with the exercise physiologist to develop a plan for
maintaining optimal exercise adherence. If injury or illness prevents exercise for ≥1
week, minutes are allowed to be made-up upon return to exercise.
Exercise compliance is monitored through the use of self-reported and objective
measures. All participants randomized to the low-dose and high-dose exercise groups
are provided with an exercise log to record the date, modality of aerobic exercise used
(any form of aerobic exercise will be acceptable, though most participants elect to use
the study provided in-home treadmill), treadmill speed and incline, average heart rate
obtained from a study-provided heart rate monitor, duration of exercise, completion of
appropriate warm up and cool down, and any new or worsening musculoskeletal
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symptoms. Participants are provided with a Polar Heart Rate Monitor (Polar Electro Inc.,
RS400, Lake Success, NY). The heart rate monitors record up to 99 sessions of
exercise. Heart rate monitor data is downloaded to a computer to enable objective
monitoring of exercise adherence. Participant exercise logs and objective heart rate
data are discussed and reviewed by the exercise physiologist to provide feedback
including encouragement, problem solving, and long-term planning to the study
participant.
For both the low-dose and high-dose exercise groups, the initial exercise dose
prescribed in week one of the study is 60 min. This relatively low volume of exercise
allows participants to gain confidence in exercising, allows for time to determine how
exercise will be integrated into their schedule, and allows the participant to work towards
a practical initial exercise goal that is not overwhelming. Exercise is titrated by 30
min·wk-1 as the participant successfully responds to the exercise dose prescribed in the
prior week. During the exercise titration phase, participants meet with the exercise
physiologist at the university research center each week to review the exercise
completed in the prior week, discuss any new musculoskeletal symptoms, side effects,
or barriers to exercise. At that time exercise is then titrated for the following week. The
planned exercise volume of the low-dose and high-dose exercise groups are 150
min·wk-1 and 300 min·wk-1, respectively. In the absence of dose-limiting toxicity, lowdose and high-dose study participants have their exercise volume fully titrated by week 4
and 9 of the study, respectively. Delivered over six months, the planned total dose of
exercise delivered to the low-dose and high-dose exercise groups is 3,720 minutes and
6,740 minutes, respectively. The intensity of all exercise is prescribed between 50 and
70% of the age-predicted maximum heart rate, consistent with that of moderate-intensity
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aerobic exercise (3-6 METs) [Ainsworth et al, 2000]. Participants are allowed to
complete exercise sessions that are ≥10 minutes to ≤75 minutes in length toward the
goal of increasing behavioral feasibility of completing the planned exercise dose.
Exercise adherence is quantified using objective heart rate monitoring. However, heart
rate monitors may fail due to technical error or exceed the available memory capacity.
In our prior dose-response exercise trial this situation occurred <5% for all exercise
sessions [Schmitz et al, 2015a, Schmitz et al, 2015b]. In this scenario, objective
monitoring is used to validate at least three weeks of self-report logs. Upon validation,
self-report logs are accepted as a valid substitute for objective heart rate data until heart
rate monitor function has been restored. Exercise adherence outcomes include the
number of minutes of exercise completed within the target heart rate range for each
week of the study and over six months, and the percent of prescribed minutes completed
in each week of the study and over six months.
Participants randomized into the usual-care control group are asked to maintain their
pre-study levels of physical activity and/or follow the recommendations provided by their
physician. After completing six month measures, control group participants are provided
with an in-home treadmill and individualized exercise program, similar to that prescribed
to the two exercise groups. Upon study completion, all participants are allowed to keep
their study-provided treadmills.
Statistical Considerations
Thirty nine participants were randomized to the three study arms (control, 150 min·wk-1,
300 min·wk-1), toward the goal of having 30 participants (10 per arm) with study endpoint
data (76% completion rate). This sample size provides adequate statistical power for
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the primary outcome biomarkers (sICAM-1 and sVICAM-1) with a hypothesis for a linear
dose-response trend. Against the hypothesis of a dose-response relationship with
decreases of 22 and 44 units for low-dose and high-dose respectively for sICAM-1 and
74 and 148 units for sVCAM-1, 30 participants provide 80% power for two tests (one for
sICAM-1 and one for sVCAM-1), each tested with a type I error rate of 0.025, to maintain
the experiment-wise overall error rate of 0.05. The estimated change in sICAM-1 and
sVCAM-1 is clinically meaningful and consistent with prior exercise interventions in noncancer populations [Adamopoulos et al, 2001, Hamdy et al, 2003, Leinonen et al, 2003,
Saetre et al, 2011, Tonjes et al, 2007].
The target sample size provides sufficient statistical power to examine key secondary
outcomes that include VAT and fasting insulin. Against the hypothesis of a doseresponse relationship with an increase in VAT of +8.6% (+14 cm2) in the control group,
+1.7% (+2.9 cm2) in the low-dose group, and -6.9% (-11.6 cm2) in the high-dose group
and a pooled standard deviation of ±17%, 30 participants provide 80% power tested with
a type I error rate of 0.05. These changes are estimated from a prior dose-response
exercise study [Slentz et al, 2005, Slentz et al, 2009, Slentz et al, 2004]. Against the
hypothesis of a dose-response relationship with an increase in fasting insulin of +1.1
μU/mL in the control group, –0.5 μU/mL in the low-dose group, and –0.9 μU/mL in the
high-dose group, and a pooled standard deviation of ±0.7 μU/mL, 30 participants provide
80% power tested with a type I error rate of 0.05. These changes are estimated from a
prior dose-response exercise study [Houmard et al, 2004]. The exploratory outcomes
for this trial include enumeration of CTCs, functional status, and patient-reported
outcomes and quality of life measures. There are limited data to determine what
proportion of colon cancer survivors who have completed adjuvant therapy for colon
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cancer will have enumerable CTCs. Further, it is unknown how exercise may impact
CTC volume. Consequently, this outcome is considered exploratory with no directional
hypothesis. We hypothesize that functional status, and patient-reported outcomes and
quality of life measures will improve in dose-response fashion.
To identify characteristics associated with inquiry about study participation and
randomization onto the study protocol we had 80% power to detect an odds ratio as
small as 1.3 and 1.7, respectively. Both sets of analyses were tested with the type I
error rate of 0.05.
Statistical Analysis
The feasibility of exercise is quantified by comparing the proportion of participants in
each group who achieve ≥80% of their prescribed exercise dose. The safety of exercise
is quantified by comparing the proportion of participants who experience adverse events
in each of the three study groups. For each of the primary and secondary physiologic
outcomes, a linear mixed-effects regression model is used to compare the change in
biomarker levels for each group while adjusting for the baseline value of the dependent
variable. All analyses follow an intention-to-treat approach. Models are fit to include
dose as a linear term, and model fit is examined using standard methods. Alternatives
to a linear dose trend include transformations of dose, such as average actual dose, logtransformed dose per week, or second-order polynomial (i.e., dose and dose2). In the
absence of a dose-response relationship, each of the two intervention groups (low-dose
and high-dose exercise) is compared to the control arm using a two-sided t-test.
Characteristics associated with inquiry about study participation and randomization onto
the study protocol are identified using two sets of logistic regression analyses: one set to
compare characteristics between those who inquired about study participation versus
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those who do not inquire about participation; and one set to compare characteristics
between those who were randomized onto the study protocol versus those who were not
randomized onto the study protocol. Characteristics with P<0.20 in univariable models
are entered simultaneously in a multivariable model.

Results
Between January and July 2015, 1,435 letters were delivered to potentially-eligible
persons with an ICD-O-3 code for colon cancer (Table 2.1). Two recipients of the study
letter expressed concern about disclosure of private health information (0.001%). These
two recipients clarified their concerns with the principal investigator and were provided
with the appropriate contact at the PCR. These two participants were excluded from the
analyses presented herein reducing the analytic sample to 1,433. Colon cancer
survivors who were invited to participate in this trial were representative of colon cancer
survivors in the United States with respect to age, sex, race, and disease stage [Siegel
et al, 2014]. The median distance from the University of Pennsylvania to the zip-code
centroid of survivors invited to participate was 20 kilometers [interquartile 25-75% range:
10-33] and ranged from 0.4 (~4 city blocks) to 71 kilometers.
Among the 1,433 colon cancer survivors invited to participate, 126 (8.8%) inquired about
participation (Figure 2.2). Eleven letters were mailed to screen one potentially-eligible
participant. In univariate analysis, colon cancer survivors who inquired about
participation were younger [Odds Ratio: 0.82 per 5-year increment (95% CI: 0.76-0.88);
P<0.001; Table 2.1], and were more likely to be treated with chemotherapy [Odds Ratio:
1.68 (95% CI: 1.15-2.44); P=0.007], compared to those who did not inquire about
participation. In a multivariable model, age was associated with inquiring about study
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participation [Odds Ratio: 0.83 per 5-year increment (95% CI: 0.77-0.89); P<0.001], but
treatment with chemotherapy was no longer statistically significant [Odds Ratio: 1.43
(95% CI: 0.98-2.10); P=0.066].
Among the 126 colon cancer survivors who inquired about participation, 102 were
screened (81%). The remaining 24 inquiries were not screened due to the study
reaching its accrual goal. Among the 102 colon cancer survivors screened, 46 (45%)
were not interested in participating after learning more about the study. The most
commonly cited reasons for not being interested in the study were: being too busy
(n=27; 59%); traveling into the city of Philadelphia would be too burdensome (n=13;
28%); having other health concerns (n=5; 11%); and not wanting to be randomized to a
group that may not include exercise (n=1; 2%). Among the 102 colon cancer survivors
screened, 17 (17%) were not eligible for participation after completing the telephone
interview. The most common reasons for ineligibility included: having a history of
another cancer (n=8; 47%); currently exercising ≥150 min·wk-1 (n=3; 18%); having a
cardiac condition (n=3; 18%); having recurrent or metastatic colon cancer (n=2; 12%);
and being ≥36 months post cancer therapy (n=1; 5%).
Among the 102 colon cancer survivors who were screened, 39 (38%) were randomized
onto the study protocol. Thirty seven letters were mailed to randomize one participant
onto the study protocol. Thirty-two participants were recruited during phase 1 eligibility
(82%; most strict, January and March letter mailings), two participants in phase 2 (5%;
less strict, May letter mailing), and five participants in phase 3 (13%; least strict, July
letter mailing). It is not clear why recruitment was most successful during the more
restrictive phases of recruitment. This may be due in part to the month in which
participants were recruited which may have influenced their willingness to participate in a
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trial of lifestyle modification. Compared with mailings in the month of January, mailings
in the months of March, May, and July were associated with lower study inquiry and
randomization rates, though these comparisons did not reach the threshold for statistical
significance. No participants had their physician decline approval to participate in the
study. In univariate analyses, colon cancer survivors who were randomized onto the
study protocol were younger [Odds Ratio: 0.69 per 5-year increment (95% CI: 0.600.78); P<0.001], and were more likely to be treated with chemotherapy [Odds Ratio: 2.66
(95% CI: 1.32-5.39); P=0.006]. In a multivariable model, age was associated with
randomization onto the study protocol [Odds Ratio: 0.70 per 5-year increment (95% CI:
0.61-0.79); P<0.001], and treatment with chemotherapy was attenuated to marginal
statistical significance [Odds Ratio: 2.01 (95% CI: 0.98-4.13); P=0.056].
Among participants randomized to one of the two exercise groups, the median time from
randomization to treadmill delivery and setup was 12 days [interquartile 25-75% range:
10-15]. The final trial participant was randomized in August 2015. Six month endpoint
data collection was completed in February 2016.

Discussion
The COURAGE trial is an NCI sponsored, phase II, randomized, dose-response exercise
trial that seeks to test the feasibility, safety, and physiologic effects of two distinct doses
of moderate-intensity aerobic exercise compared to a usual-care control group among
colon cancer survivors. The results of this trial will provide preliminary information
regarding the appropriate dose of aerobic exercise to optimize biomarkers that may
mediate the relationship between exercise and colon cancer recurrence and clarify
important design aspects for future phase 2 and phase 3 randomized controlled trials.
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The primary recruitment method for the COURAGE trial was postal mailings to potentiallyeligible colon cancer survivors identified within the PCR. Historically the recruitment of
survivors of colon cancer into lifestyle modification trials has been challenging [Courneya
et al, 2014, Ligibel et al, 2012, Meyerhardt, 2013, Pinto et al, 2013, van Waart et al,
2015]. The reasons for this have not been fully explained, but may be due in part to the
fact that colon cancer survivors are often older, have other comorbid health conditions,
or residual toxicity from treatment (i.e., neuropathy), each of which may influence
willingness to participate in a program of lifestyle modification [Brown and Schmitz,
2014b]. Several studies have described their experience in recruiting colon cancer
survivors into trials of lifestyle modification. Pinto et al. recruited colon cancer survivors
to a telephone-based physical activity intervention that aimed to increase participation in
physical activity and improve self-reported quality-of-life outcomes [Pinto et al, 2013].
Despite implementing various recruitment strategies (informational mailings, in-clinic
recruitment, and community presentations), they were unable to recruit the required
sample size of 134 participants; only randomizing 46 colon cancer survivors over 39
months (~1.5 participants per month). The CHALLENGE trial is a randomized phase 3 trial
that seeks to recruit high-risk stage II and stage III colon cancer survivors to a three year
physical activity program that aims to improve disease-free survival [Courneya et al,
2008]. When the CHALLENGE trial was designed, recruitment of 962 colon cancer
survivors was estimated to require 36 months (~27 participants per month). Despite
being open at 20 centers in Canada and 22 centers in Australia, over 55-months, 250
colon cancer survivors have been randomized (~4.5 participants per month) [Courneya
et al, 2014]. At a single institution over seven months, the COURAGE trial randomized 39
colon cancer survivors (~5.5 participants per month). At the time the trial met its planned
accrual goal and closed to enrollment, an additional 24 potentially-eligible colon cancer
47

survivors expressed interest in participating and were waiting to be screened for trial
enrollment.
Each of the above-described trials is unique in their eligibility criteria, intervention
characteristics, and endpoints of interest; our recruitment experience indicates that
utilizing population-based cancer registries to recruit colon cancer survivors into a
lifestyle modification trial is feasible. The use of population-based cancer registries is
disseminable to other cancer centers for accrual in multicenter trials, and may help to
address an important barrier in the conduct of future lifestyle modification trials in this
population. A potential limitation to the use of population-based cancer registries is the
six to nine month delay that may occur from the time of diagnosis to entry into the
registry. This limitation is of importance for trials that seek to modify behavior during or
shortly after the completion of adjuvant therapy. To address this limitation, many cancer
registries now offer rapid case ascertainment which accelerates the reporting process to
within one month of diagnosis [Beskow et al, 2006]. Another explanation to the high
inquiry and screening rates in this study was the provision of an in-home treadmill. The
mailed flyer did describe this novel feature of the study. As intended, this may have
provided additional incentive to inquire about participation. Given the potential benefit of
exercise to improve disease outcomes, developing methods to recruit colon cancer
survivors to participate in lifestyle modification trials is of critically high importance.
Colon cancer survivors who inquired about trial participation were younger than those
who did not inquire about trial participation. Similarly, colon cancer survivors who were
randomized onto the trial protocol were younger than those who were not randomized.
This pattern is common to many trials, regardless of the intervention. In an analysis of
21 Southwest Oncology Group (SWOG) therapeutic trials that included 5,190 cancer
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patients with 21 types of cancer, trial enrollees were significantly younger than nonenrollees (P<0.001) [Unger et al, 2014]. These findings underscore the need for
continued research to identify methods to communicate opportunities about clinical trial
participation to older adults in an efficient and scalable manner. In our multivariable
model, treatment with chemotherapy was of marginal statistical significance for both
inquiry about study participation (P=0.066) and randomization onto the study protocol
(P=0.056). This finding indicates the interest of patients with a higher probability of
recurrence (i.e., high-risk stage II and stage III) to inquire and participate in a clinical trial
of lifestyle modification. Collectively, these data indicate that with exception of age,
COURAGE

trial participants are similar to the broader community of colon cancer survivors

on measured characteristics, such as sex, race, time since diagnosis, clinico-pathologic
tumor features, and geographic proximity to the University of Pennsylvania.
In addition to obtaining important information about the feasibility and safety of the doseresponse effects of exercise among colon cancer survivors, this trial will gather
preliminary data regarding physiologic changes in biomarkers that are hypothesized to
mediate the relationship between exercise and disease outcomes. sICAM-1 and
sVCAM-1 are cell-adhesion molecules that promote the growth of existing micrometastases, and promote CTC differentiation, contact inhibition, and apoptosis [Paschos
et al, 2009]. The down regulation of ICAM-1 attenuates the invasive potential of colon
cancer cells and has been recommended as a therapeutic target [Howard et al, 2014].
VCAM-1 has also been recommended as a therapeutic target [Schlesinger and Bendas,
2015]. ICAM-1 and VCAM-1 have also been demonstrated to influence the metastatic
potential of melanoma and gastric cancers [Giavazzi et al, 1992, Nakashio et al, 1997].
We hypothesize that exercise may inhibit both seeding of distant organs and the
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cultivation of the angiogenic milieu that is thought to be required for the growth of micrometastases. We speculate that exercise may have direct effects on anti-cancer
myokines, such as secreted protein acidic and rich in cysteine (SPARC) [Aoi et al, 2013],
and may also have indirect effects through pathways that include improved metabolic
homeostasis (i.e., VAT and insulin). Several studies have demonstrated that abdominal
adiposity, particularly VAT, is associated with poor colon cancer outcomes [Ballian et al,
2012, Guiu et al, 2010, Haydon et al, 2006a, Moon et al, 2008, Prizment et al, 2010,
Rickles et al, 2013]. VAT associates with insulin among colon cancer survivors (r=0.519;
P<0.001) [Jiang et al, 2014], and is implicated in the recurrence of colon cancer
[Giovannucci, 2001, Sandhu et al, 2002]. We hypothesize that exercise may reduce
VAT and fasting insulin and potentially inhibit the growth of existing micro-metastases.
As an exploratory aim, we will examine CTCs using the innovative GEDI platform
[Gleghorn et al, 2010]. We hypothesize that CTCs disseminate via the circulation during
the earliest stages of recurrent metastatic growth, mirroring what occurs during the
primary tumor setting. If this does indeed occur, we are uniquely situated to detect this
phenomenon using GEDI. If exercise delays or inhibits metastases, this may be
reflected in CTC concentration.
There are several strengths of this trial. The use of two intervention groups, each
prescribed a distinct dose of exercise will allow us examine how feasibility, safety, and
physiologic effects differ along the exercise dose curve. Given the eligibly criteria, these
two different doses of exercise will require that some participants modestly increase their
exercise and others to increase over 10-fold. The exercise intervention was designed to
allow for scalability to larger phase 2 and ultimately a phase 3 clinical trial. The exercise
program allows for flexibility, emphasizing a home-based program, blended with
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supervised training and ongoing behavioral and clinical support from an exercise
physiologist. The provision of home-based treadmills serves a dual purpose of providing
a reasonable incentive for participation, and promoting feasibility and favorable
adherence to the exercise prescription over six months.
There exist several limitations to this trial. The primary limitation to this study is the
small sample size which may limit interpretation of the study findings. However, this
study was designed to gather important feasibility, safety, and preliminary physiologic
data to refine important design aspects for future phase 2 and phase 3 trials. We
acknowledge 300 min·wk-1 is a large weekly dose of aerobic exercise. We elected to
compare 150 and 300 min·wk-1 of aerobic exercise to complement ongoing work which
prescribes 225 min·wk-1 [Courneya et al, 2008, Meyerhardt, 2013] and to parallel the
epidemiologic data that suggest a dose-response relationship with disease outcomes
[Campbell et al, 2013, Des Guetz et al, 2013, Je et al, 2013, Kuiper et al, 2012,
Meyerhardt et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009, Schmid and
Leitzmann, 2014]. Our research team has been successful in promoting adherence to
the prescription of 300 min·wk-1 of aerobic exercise in our prior studies [Schmitz et al,
2015a, Schmitz et al, 2015b]. The high-dose exercise group received five additional inperson sessions with the exercise physiologist which may differentially impact
adherence rates between the low-dose and high-dose exercise groups. Although VAT
and fasting insulin are secondary outcomes of this trial, participants were not recruited
on the basis of being overweight or obese at baseline and/or having high levels of
fasting insulin. Consequently this may limit our ability to detect significant exerciseinduced improvements in these outcomes. We considered the inclusion of survivors of
rectal cancer, but restricted inclusion to colon cancer survivors, as there is limited
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evidence to support the benefit of exercise in improving rectal cancer outcomes
[Meyerhardt et al, 2009].

Conclusion
In conclusion, the findings from this trial will be useful in understanding the feasibility,
safety, and physiologic effects of two doses of aerobic exercise among colon cancer
survivors. These findings contribute toward the goal of conducting a definitive trial to
assess the effects of exercise on disease outcomes among colon cancer survivors.
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Table 2.1 Demographic, clinical, and recruitment characteristics associated with study
inquiry and randomization.
Invited to
Participate
(n=1,433)
Characteristic
Age,c y
<70 y
≥70 y
Sex, n (%)
Male
Female
Race, n (%)
White
Nonwhite
Missing or Unknown
Time Since Diagnosis,c
mo
≤12 mo.
12-18 mo.
≥18 mo.
Anatomical Location, n
(%)
Left Colon
Right Colon
Unknown or Multiple
AJCC Stage,d n (%)
I
II
III
Invasion Through Bowel
Wall (T Stage), n (%)
T1
T2
T3
T4
Lymph Node Involvement
(N Stage), n (%)
N0 (0)
N1 (1-3)
N2 (≥4)
Grade of Differentiation, n
(%)
Well (low)
Moderate
(intermediate)
Poor or
Undifferentiated (high)
Unknown
Lymphovascular
Invasion, n (%)
Absent
Present
Unknown
Chemotherapy, n (%)
Month Study Letter
Mailed, n (%)
January
March
May
July
Distance to Institution,c
km

n (%) or
Median [IQR]
68 [58-77]
769 (54%)
664 (46%)

Inquired about Participation
(n=126)
n (%) or
Median
[IQR]
OR (95% CI)a
59 [53-59]
0.82 (0.76-0.88)
95 (75%)
1.00
31 (25%)
0.35 (0.23-0.53)

710 (50%)
723 (50%)

55 (44%)
71 (56%)

1.00
1.29 (0.90-1.87)

0.167

1,086 (76%)
320 (22%)
27 (2%)
16 [10-22]

97 (77%)
29 (23%)
0 (0%)
16 [11-21]

1.00
1.02 (0.66-1.57)
—

0.943
—

466 (32%)
384 (27%)
583 (41%)

37 (29%)
36 (29%)
53 (42%)

1.00
1.20 (0.74-1.94)
1.16 (0.75-1.80)

0.458
0.509

14 (36%)
8 (20%)
17 (44%)

1.00
0.69 (0.28-1.65)
0.97 (0.47-1.99)

0.403
0.933

534 (38%)
866 (60%)
33 (2%)

57 (45%)
67 (53%)
2 (2%)

1.00
0.70 (0.48-1.02)
0.54 (0.13-2.31)

0.061
0.407

18 (46%)
21 (54%)
0 (0%)

1.00
0.71 (0.38-1.35)
—

0.298
—

349 (24%)
523 (37%)
561 (39%)

28 (22%)
44 (35%)
54 (43%)

1.00
1.05 (0.64-1.73)
1.22 (0.76-1.97)

0.838
0.412

5 (13%)
14 (36%)
20 (51%)

1.00
1.89 (0.67-5.30)
2.54 (0.95-6.84)

0.225
0.064

247 (17%)
174 (12%)
773 (54%)
239 (17%)

23 (18%)
10 (8%)
74 (59%)
19 (15%)

1.00
0.59 (0.27-1.28)
1.03 (0.63-1.68)
0.84 (0.44-1.59)

0.184
0.903
0.594

4 (10%)
2 (5%)
25 (64%)
8 (21%)

1.00
0.71 (0.13-3.90)
2.03 (0.70-5.89)
2.10 (0.62-7.08)

0.690
0.193
0.230

872 (61%)
381 (27%)
180 (12%)

72 (57%)
34 (27%)
20 (16%)

1.00
1.09 (0.71-1.67)
1.39 (0.82-2.34)

0.696
0.219

19 (49%)
15 (38%)
5 (13%)

1.00
1.84 (0.92-3.66)
1.28 (0.47-3.48)

0.082
0.625

123 (9%)
940 (66%)

6 (5%)
85 (67%)

1.00
1.94 (0.83-4.54)

0.127

2 (5%)
29 (74%)

1.00
1.92 (0.45-8.17)

0.374

275 (19%)

25 (20%)

1.94 (0.78-4.88)

0.154

5 (13%)

1.12 (0.21-5.85)

0.893

95 (6%)

10 (8%)

2.29 (0.80-6.56)

0.121

3 (8%)

1.97 (0.3212.05)

0.462

876 (61%)
391 (27%)
166 (12%)
709 (50%)

73 (58%)
36 (29%)
17 (13%)
77 (61%)

1.00
1.11 (0.73-1.69)
1.25 (0.72-2.19)
1.68 (1.15-2.44)

0.609
0.423
0.007

23 (59%)
12 (31%)
4 (10%)
28 (72%)

1.00
1.17 (0.58-2.38)
0.91 (0.31-2.68)
2.66 (1.32-5.39)

0.657
0.872
0.006

865 (60%)
100 (7%)
119 (8%)
349 (24%)
20 [10-34]

85 (67%)
7 (6%)
6 (5%)
28 (22%)
21 [9-26]

1.00
0.69 (0.31-1.54)
0.49 (0.21-1.14)
0.80 (0.51-1.25)
1.03 (0.97-1.09)

0.365
0.098
0.328
0.327

31 (79%)
1 (3%)
2 (5%)
5 (13%)
20 [9-40]

1.00
0.27 (0.04-2.01)
0.46 (0.11-1.94)
0.39 (0.15-1.01)
1.07 (0.97-1.17)

0.202
0.291
0.053
0.182
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<0.001

Randomized
(n=39)
n (%) or
Median
[IQR]
55 [47-61]
36 (92%)
3 (8%)

OR (95% CI)b
0.69 (0.60-0.78)
1.00
0.09 (0.03-0.30)

15 (38%)
24 (62%)

1.00
1.59 (0.83-3.06)

0.164

31 (79%)
8 (21%)
0 (0%)
15 [10-21]

1.00
1.59 (0.83-3.06)
—

0.164
—

P
<0.001

P
<0.001
<0.001

Odds Ratio (OR) and 95% Confidence Interval (CI) comparing those who inquired about participation to those who were invited to participate.
Odds Ratio (OR) and 95% Confidence Interval (CI) comparing those who were randomized to those who were invited to participate.
cMedian and Interquartile [25-75%] range.
dAJCC: American Joint Committee on Cancer (7th edition).
a
b
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Figure 2.1 Study Schema
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Figure 2.2 CONSORT Diagram
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Abstract
Background: Physical activity is associated with a lower risk of disease recurrence
among colon cancer survivors. Excess visceral adipose tissue (VAT) is associated with
a higher risk of disease recurrence among colon cancer survivors. The pathways
through which physical activity alters disease outcomes are unknown, but may be
mediated by changes in VAT.
Methods: Between January 2015 and August 2015, 39 stage I-III colon cancer survivors
were randomized to one of three groups: usual-care control, 150 min·wk-1 of aerobic
exercise (low-dose), and 300 min·wk-1 of aerobic exercise (high-dose) for six months.
The pre-specified key body composition outcome was VAT quantified using dual energy
x-ray absorptiometry. Other body composition outcomes were exploratory.
Results: Exercise reduced VAT in dose-response fashion (Ptrend=0.008). Compared to
the control group, the low-dose and high-dose exercise groups lost 9.5 cm2 (95% CI: –
22.4, 3.5) and 13.6 cm2 (95% CI: –27.0, –0.1) in VAT, respectively. Each 60 min·wk-1
increase in exercise predicted a 2.7 cm2 (95% CI: –5.4, –0.1) reduction in VAT. Exercise
reduced waist circumference in dose-response fashion (Ptrend<0.001). Compared to the
control group, the low-dose and high-dose exercise groups lost 1.5 cm (95% CI: –4.0,
1.1) and 4.5 cm (95% CI: −7.1, –1.9) in waist circumference, respectively. Each 60
min·wk-1 increase in exercise predicted a 0.9 cm (95% CI: –1.4, –0.4) reduction in waist
circumference.
Conclusion: Aerobic exercise reduces VAT in dose-response fashion among patients
with stage I-III colon cancer. Continued research to elucidate the mechanistic pathways
through which physical activity alters disease outcomes is warranted.
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Introduction
Each year 83,000 people are diagnosed with non-metastatic colon cancer in the United
States [Siegel et al, 2014]. Despite efficacious surgical and chemotherapeutic
interventions, 25-40% will experience recurrent and metastatic disease within threeyears of diagnosis [André et al, 2004, Clinical Outcomes of Surgical Therapy Study
Group, 2004, Quasar Collaborative Group, 2007], and 91% of those who recur within
three-years, die by five-years [Sargent et al, 2005]. Therefore it is critical to study
additional therapies that reduce the risk of recurrent disease and promote long-term
survival in this population.
Participation in physical activity after diagnosis of colon cancer is associated with a lower
risk of recurrence and mortality [Meyerhardt et al, 2006]. This observation is
independent of various demographic, clinico-pathologic, and treatment-related
prognostic factors [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006,
Meyerhardt et al, 2006, Meyerhardt et al, 2009]. A consistently reported observation is
that post-diagnosis physical activity is associated with disease outcomes in a doseresponse fashion, such that larger doses of physical activity or exercise, up to
approximately 300 minutes per week (min·wk-1), are associated with more favorable
disease outcomes [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006,
Meyerhardt et al, 2006, Meyerhardt et al, 2009].
The biologic or biobehavioral pathways through which exercise may favorably alter
disease outcomes among colon cancer survivors are unknown. One plausible pathway
includes exercise-induced alterations in body composition [Parkin et al, 2014]. Excess
visceral adipose tissue (VAT) is associated with an increased risk of disease recurrence
and mortality among colon cancer survivors [Lee et al, 2015, Moon et al, 2008, Rickles
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et al, 2013]. In addition, waist circumference (an anthropometric proxy for VAT) is
associated with cancer-specific and all-cause mortality among colon cancer survivors
[Haydon et al, 2006a]. These observations are further strengthened by evidence that
the VAT of colon cancer survivors exhibits extensive metabolomic activity [Liesenfeld et
al, 2015], and polymorphisms within adiposity-related genes predict disease recurrence
among colon cancer survivors [Sebio et al, 2015].
Exercise reduces VAT among non-diabetic persons with obesity in a dose-response
fashion [Slentz et al, 2005]; however the dose-response effects of exercise on VAT and
other body composition measures, such as waist circumference, have not been
examined among colon cancer survivors. Understanding how exercise may alter
pathways that are hypothesized to influence disease outcomes and the sensitivity of
such pathways to respond to different doses of exercise will help to improve the
specificity of exercise prescriptions in this population, and provide experimental evidence
to support the findings of observational studies that document the benefits effects of
exercise among colon cancer survivors.
The COURAGE trial was a randomized controlled trial with the primary aim of examining
the safety, feasibility, and biological efficacy of 150 and 300 min·wk-1 of aerobic exercise
versus usual care control over six months among men and women with a history of nonmetastatic colon cancer [Brown et al, 2016]. Here we report body composition
outcomes. VAT quantified using dual-energy x-ray absorptiometry (DXA) was prespecified as the key body composition outcome of this trial. Our hypothesis was that
exercise would reduce VAT in a dose-response fashion.
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Methods
Participants
Detailed study methods of the COURAGE trial were published previously [Brown et al,
2016]. Potentially-eligible participants were recruited throughout the metropolitan
Philadelphia region. Participants were eligible if they: 1) were diagnosed with
histologically-proven stage I-III colon cancer; 2) completed surgical resection and
adjuvant chemotherapy within 36 months of entering the study; 3) self-reported
participating in ≤150 min·wk-1 of moderate or vigorous intensity physical activity using the
Paffenbarger Physical Activity Questionnaire [20]; 4) were of age ≥18 years; 5) provided
written physician approval; 6) had no additional surgery planned within the six month
intervention period (including colostomy reversal); 7) had the ability to walk unaided for
six minutes. Participants were ineligible if they: 1) had a history of another primary
cancer (other than non-melanoma skin-cancer); 2) had evidence of metastatic cancer; 3)
were pregnant or breast feeding; 4) were unable to provide a baseline blood sample; 5)
had a myocardial infarction or coronary revascularization procedure within the past three
months; 6) had uncontrolled hypertension, defined as a systolic blood pressure ≥180
mm Hg or diastolic blood pressure ≥100 mm Hg; 7) had high-risk or uncontrolled heart
arrhythmias (not including atrial fibrillation); 8) had clinically significant heart valve
disease; 9) had decompensated heart failure; 10) had a known aortic aneurysm; or 11)
had any other condition which, in the opinion of the investigator, may impede testing of
study hypotheses or make it unsafe to engage in the exercise program.
Participants were stratified on cancer stage (AJCC 7th Edition: I vs II vs III) and
randomized into one of three groups: low-dose aerobic exercise (150 min·wk-1), highdose aerobic exercise (300 min·wk-1), or usual care control. This study was approved by
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the University of Pennsylvania Institutional Review Board. Participants provided written
informed consent and written approval from their physician prior to participation.
Intervention
Aerobic exercise was performed over six months using study-provided in-home
treadmills (LifeSpan Fitness, TR1200i, Salt Lake City, UT). Participants were provided
with a heart rate monitor to objectively record heart rate during each exercise session.
Participants also used exercise logs to record the date, time, average heart rate, and
exercise duration. Participants met with a clinical exercise physiologist to introduce the
exercise prescription, and familiarize the participant with use of the treadmill, completion
of exercise logs, use of a heart rate monitor, appropriate warm-up and cool-down,
stretches, and proper footwear for aerobic exercise. Participants were encouraged to
individualize their frequency (days per week), fractionation (sessions per day), and
duration (minutes per day) of exercise according to a schedule that promoted a high
level of adherence to the prescribed exercise volume. The exercise physiologist
provided ongoing behavioral and clinical support and monitored exercise adherence to
the study protocol throughout the duration of the study through the use of weekly
telephone and email communications. Exercise intensity was prescribed at 50-70% of
the age-predicted maximum heart rate (3-6 METs [Ainsworth et al, 2000]). The low-dose
and high-dose groups progressed towards of the goal of 150 or 300 min·wk-1 of exercise,
respectively. Detailed methods of the exercise intervention were published previously
[Brown et al, 2016].
Participants randomized into the usual-care control group were asked to maintain their
pre-study levels of physical activity and/or follow the recommendations provided by their
physician. After completing six month measures, control group participants were
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provided with an in-home treadmill and individualized exercise program, similar to that
prescribed to the two exercise groups. Upon study completion, all participants were
allowed to keep their study-provided treadmills.
Measurements
Baseline and follow-up measurements were obtained by trained staff members who
were blinded to treatment assignment. Demographic characteristics including age, sex,
race, and education were self-reported. Smoking status was obtained from a
standardized questionnaire [Pleis et al, 2009]. Daily caloric intake was quantified using
three-day food records that were analyzed by a registered dietitian using the Nutrition
Data System for Research software (v.2014). Moderate to vigorous intensity physical
activity was quantified using an accelerometer (ActiGraph GT3X+) with validated cutpoints [Troiano et al, 2008]. Clinical information including cancer stage, treatment with
chemotherapy, and performance status were obtained from the Pennsylvania State
Cancer Registry, pathology reports, or physician records. Five-year predicted overall
survival was calculated using a validated prognostic model for colon cancer [Weiser et
al, 2011].
Body Composition Outcomes
The pre-specified key body composition outcome was VAT quantified using DXA. All
other body composition outcomes were considered exploratory. All participants
underwent whole-body DXA (Hologic Horizon, Bedford MA). All DXA scans were
reviewed for quality assurance by a certified DXA technician who was blinded to study
group [Powers et al, 2014]. The DXA scanner was calibrated daily using an
anthropomorphic spine phantom and thrice weekly using a whole body phantom. DXA
was used to quantify VAT (cm2), subcutaneous adipose tissue (cm2), fat mass (kg), lean
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mass (kg), and bone mineral density (g/m2) using Hologic APEX v.13.5 software. DXAderived VAT has been validated against computed tomography-derived VAT (r=0.93;
P<0.001) [Micklesfield et al, 2012], and has been used across a large body mass
spectrum [Bredella et al, 2013]. Other anthropometric outcomes that were measured in
duplicate included height (m), body mass (kg), waist & hip circumferences (cm), and
sagittal abdominal diameter (cm). Height and body mass were used to calculate body
mass index (BMI; kg/m2).
Statistical Analysis
Descriptive statistics presented for baseline variables include counts and proportions for
categorical variables and means ± standard deviations for continuous variables.
Categorical baseline characteristics were compared among the three groups using
Fisher’s exact test, and continuous baseline characteristics were compared among the
three study groups using the Kruskal-Wallis test. Based on prior research [Slentz et al,
2005, Slentz et al, 2009, Slentz et al, 2004], we estimated a change in VAT of +14 cm2
(+8.6%) in the control group, +2.9 cm2 (+1.7%) in the low-dose group, and –11.6 cm2
(−6.9%) in the high-dose group with a pooled standard deviation of ±11 cm2 (±17%) over
six months. Against the hypothesis of a dose-response relationship, 39 participants
provided ≥80% power with a type I error rate of 5% (α=0.05). All inferential analyses
were conducted on an intention-to-treat basis. Change in VAT (and other outcomes)
was evaluated from baseline to six months in the three groups using repeated-measures
mixed-effects regression models. This statistical approach includes all available data
and accounts for the correlation between repeated measures. The baseline value of the
dependent variable and cancer stage (randomization stratification factor) were included
as covariates in the regression models [Fitzmaurice et al, 2004]. Group-by-time
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interaction terms were estimated as fixed-effects in the regression model. Results from
the repeated-measures mixed-effects regression models are presented as least-square
means (LS Mean) ± standard error (SE). To evaluate the presence of a dose-response
relationship across randomized groups, a test of trend was conducted by examining
linear contrasts. All statistical analyses were completed using Stata/MP Version 14.1
(StataCorp, College Station, TX).

Results
Between January 2015 and August 2015, 39 colon cancer survivors were recruited and
randomized with data collection ending in February 2016. Baseline characteristics of
study participants are presented in Table 3.1. Age ranged from 35–81 years. BMI
ranged from 20–43 kg/m2; 51% of participants were obese (BMI ≥30 kg/m2).
Objectively-measured moderate to vigorous intensity physical activity ranged from 3–34
min·d-1; 61% of participants self-reported not participating in any physical activity since
their colon cancer diagnosis. Time since finishing colon cancer treatment ranged from
1–21 months. Five-year predicted overall survival ranged from 35–92%. Figure 3.1
shows the flow of the 39 randomized participants through the study. One participant
was lost to follow-up (97% follow-up rate).
Exercise prescription program variables are presented in Table 3.2. Over six months,
adherence to the prescribed volumes of exercise in the low-dose and high-dose groups
were 92.8±2.44% and 89.0±2.64%, respectively (P=0.287). Average exercise volume in
the low-dose and high-dose groups were 141.5±9.92 min·wk-1 and 247.2±10.71 min·wk1

, respectively (∆ between groups: 105.7±14.60; P<0.001). The high-dose group

exercised on more days per week (P=0.001), more sessions per day (P=0.001), longer
duration per session (P<0.001), and required more weeks to progress to the full dose of
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prescribed exercise (P=0.007), as compared to the low-dose group. Exercise intensity
was 70.7±0.85% of the age-predicted maximal heart rate, the proportion of exercise
sessions using the study-provided treadmill was 76.5±9.4%, and the proportion of
exercise sessions validated with objective heart rate data was 96.8±0.59%, all of which
did not differ between the two exercise groups. Accelerometer-quantified moderate to
vigorous intensity physical activity increased in dose-response fashion (Ptrend<0.001);
over six months the control group increased by 4.2±6.5 min·d-1, whereas the low-dose
and high-dose groups increased by 26.5±6.1 and 33.1±6.5 min·d-1, respectively.
Body composition outcomes are presented in Table 3.3. At baseline, no differences in
body composition were observed among the three groups. Exercise reduced VAT, the
pre-specified key body composition outcome, in dose-response fashion (Ptrend=0.008;
Figure 3.2A). Compared to the control group, the low-dose and high-dose exercise
groups lost 9.5 cm2 (95% CI: –22.4, 3.5) and 13.6 cm2 (95% CI: –27.0, –0.1) in VAT,
respectively. Each 60 min·wk-1 increase in exercise predicted a 2.7 cm2 (95% CI: –5.4, –
0.1) reduction in VAT. This finding was reinforced by the observation that exercise
reduced waist circumference (an anthropometric proxy for VAT) in dose-response
fashion (Ptrend<0.001; Figure 3.2B). Compared to the control group, the low-dose and
high-dose exercise groups lost 1.5 cm (95% CI: –4.0, 1.1) and 4.5 cm (95% CI:–7.1, –
1.9) in waist circumference, respectively. Each 60 min·wk-1 increase in exercise
predicted a 0.9 cm (95% CI: –1.4, –0.4) reduction in waist circumference. Changes in
VAT were correlated with changes in waist circumference (r=0.42; P=0.009).
Improvements in waist-to-hip ratio were of marginal significance (Ptrend=0.054). An
unexpected finding was the observed improvement in bone mineral density
(Ptrend=0.015). Compared to the control group, the low-dose and high-dose exercise
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groups gained 0.015 g/m2 (95% CI: 0.001, 0.029) and 0.013 g/m2 (95% CI: -0.001, 0.028)
in bone mineral density, respectively. This improvement was not hypothesized to occur
and bone mineral density was an exploratory outcome; therefore, this finding should be
viewed as hypothesis generating and may be a type I error (false positive). No
significant change in body mass was observed (Ptrend=0.280), this was expected
because self-reported caloric consumption did not change (Ptrend=0.743). No serious
(grade ≥3) adverse events occurred.

Discussion
A six month moderate-intensity aerobic exercise program among stage I-III colon cancer
survivors resulted in significant linear dose-response reductions in VAT measured by
DXA and waist circumference. The findings from this randomized trial provide
mechanistic data to support observational evidence that suggests physical activity may
lower the risk of recurrence and mortality among colon cancer survivors.
The linear reductions in VAT and waist circumference with increasing exercise volume
are similar to prior dose-response exercise interventions in other populations (reviewed
here [Kay and Singh, 2006]). For example, among overweight and obese men and
women with dyslipidemia, increasing exercise volume was associated with larger
reductions in VAT [Slentz et al, 2005], and waist circumference [Slentz et al, 2004]. In
our study, the usual-care control group increased VAT and waist circumference over six
months. This observation has been reported in the control groups of prior exercise trials
[Slentz et al, 2005, Slentz et al, 2004], and underscores the deleterious effect of
continued sedentary behavior. Excess energy is preferentially stored as VAT during
extended periods of inactivity [Belavý et al, 2014]. It is also important to note that we did
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not observe significant changes in body mass. Exercise preferentially utilizes VAT as an
energetic substrate, often without altering total body mass [Johnson et al, 2009, Lee et
al, 2005]. Healthcare providers who prescribe exercise to colon cancer survivors should
inform patients that exercise may not significantly reduce body mass, and that body
mass alone should not be used as an indicator of exercise success, as important
physiologic changes are likely to occur in the absence of weight loss.
The biologic or biobehavioral pathways through which exercise may favorably alter
disease outcomes among colon cancer survivors are unknown. Excess VAT and waist
circumference are associated with an increased risk of disease recurrence and mortality
among colon cancer survivors [Haydon et al, 2006a, Lee et al, 2015, Moon et al, 2008,
Rickles et al, 2013]. VAT is an active endocrine organ that secretes various bioactive
compounds such as adipokines, cytokines, hormone-like factors, and other metabolites
[Ahima and Flier, 2000, Balistreri et al, 2010, Liesenfeld et al, 2015] that have been
hypothesized to influence disease recurrence and progression [Park et al, 2014].
Excess VAT and other states associated with adiposity such as hyperinsulinemia
activate the PI3K-Akt-mTOR pathway [McCurdy and Klemm, 2013]. Activation of the
PI3K-Akt-mTOR pathway is associated with the growth and progression of colon cancer
metastases [Gulhati et al, 2011], and silencing of this pathway inhibits the growth of
metastases by inducing cell-cycle arrest and apoptosis [Zhang et al, 2009]. Several
polymorphisms within adiposity-related genes predict disease recurrence among colon
cancer survivors [Sebio et al, 2015]. For example, PPAR-γ rs1801282 regulates
transcription factors for several genes that influence colon cancer growth [Sarraf et al,
1998]. Furthermore, PPAR-γ rs1801282 predicts the progression from impaired glucose
tolerance to type 2 diabetes [Brito et al, 2009, Kilpelainen et al, 2008]. Participation in
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physical activity significantly reduces the risk of progression from impaired glucose
tolerance to type 2 diabetes that is associated with this polymorphism [Brito et al, 2009,
Kilpelainen et al, 2008]. Type 2 diabetes is associated with a worsened prognosis in
colon cancer [Jeon et al, 2013, Meyerhardt et al, 2003]. Future research will be needed
to discern if the disease-specific benefits of physical activity for colon cancer survivors
are achieved through similar pathways.
There are several limitations to this trial. The primary limitation to this trial is the small
sample size, which limited our statistical power to examine other body composition
outcomes. The small sample size also reduces the generalizability of our findings. As
we have previously described [Brown et al, 2016], trial participants were younger than
the population from which they were recruited. This has important implications for the
generalizability of our findings to the broader population of colon cancer survivors. The
duration of the exercise intervention was six months, which is modest relative to other
trials of 12 to 36 months. It is unknown if the dose-response effects of exercise on VAT
are maximized or sustained over longer periods of time. Trial participants were not
recruited on the basis of having high levels of VAT. It is unknown if the exercise-induced
reductions in VAT would be similar or larger in magnitude among a sample with high
levels of VAT at baseline.
There are several strengths to this trial. The use of two intervention groups, each
prescribed a distinct dose of exercise, allowed us examine how VAT responded along
the exercise dose curve. The exercise program was flexible, emphasizing a homebased program, blended with ongoing behavioral and clinical support from an exercise
physiologist. The provision of home-based treadmills succeeded in providing a
reasonable incentive for participation as recruitment was completed ahead of schedule,
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and succeeded in promoting favorable adherence to the exercise prescription over six
months. Completion of the prescribed exercise dose was objectively quantified using
heart-rate monitors with long-term (≥3 month) memory. Data collection was completed
by staff blinded to study group who followed standardized protocols. Participants in this
trial had later stage of disease than the population from which they were recruited
[Brown et al, 2016], which represents colon cancer survivors at highest risk for disease
recurrence. Participants had a variety of comorbid conditions that are common among
colon cancer survivors including hypertension, hyperlipidemia, diabetes, and
cardiovascular disease. Endpoint data collection was satisfactory (97% complete).
In conclusion, the findings from this randomized trial demonstrate the dose-response
effects of moderate intensity aerobic exercise to favorably reduce VAT among selected
patients recently treated for stage I-III colon cancer. The findings from this randomized
trial may be useful to healthcare providers to improve the specificity of exercise
prescriptions for colon cancer survivors. The findings from this randomized trial are also
useful to investigators to begin to understand the mechanistic pathways that are
hypothesized to mediate the relationship between exercise and disease outcomes in this
population. Continued research to elucidate the mechanistic pathways through which
physical activity alters disease outcomes is warranted.
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Table 3.1 Baseline characteristics of the participants
Total
Control
Characteristic
(n=39)
(n=13)
Age, years
56.5±10.0
57.9±9.7
Sex, %
Male
15 (38%)
4 (31%)
Female
24 (62%)
9 (69%)
Race, %
White
31 (80%)
8 (62%)
Black
6 (15%)
3 (23%)
Other
2 (5%)
2 (15%)
Education, %
High School or Less
7 (18%)
1 (8%)
Some College
8 (20%)
3 (23%)
College Degree or More
24 (62%)
9 (69%)
Smoking History, %
Never
23 (59%)
10 (77%)
Former
14 (36%)
3 (23%)
Current
2 (5%)
0 (0%)
-1
1747±542
1749±545
Caloric Consumption, kcal·d
15.7±8.7
12.2±8.1
Moderate or Vigorous Physical
Activity, min·d-1
Body Mass Index, kg·m-2
30.3±5.8
29.2±6.0
Stage, %
I
5 (13%)
1 (8%)
II
14 (36%)
5 (38%)
III
20 (51%)
7 (54%)
Chemotherapy, %
28 (72%)
10 (77%)
Time Since Treatment
10.9±6.1
11.3±6.7
Completion, Months
ECOG Performance Status, %
0, Fully active
29 (74%)
10 (77%)
1, Ambulatory, but restricted in
10 (26%)
3 (23%)
strenuous activity
Comorbid Conditions, %
Hypertension
13 (33%)
4 (31%)
Hyperlipidemia
6 (15%)
1 (8%)
Type 2 Diabetes
5 (13%)
1 (8%)
Cardiovascular Disease
4 (10%)
2 (15%)
5-Year Predicted Survival, %
68 [60-87]
68 [61-85]
P values are from the overall test of group differences.
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Low-Dose
(n=14)
58.2±9.8

High-Dose
(n=12)
53.1±10.5

7 (50%)
7 (50%)

4 (33%)
8 (67%)

0.601

12 (86%)
2 (14%)
0 (0%)

11 (92%)
1 (8%)
0 (0%)

0.332

4 (29%)
2 (14%)
8 (57%)

2 (17%)
3 (25%)
7 (58%)

0.765

6 (43%)
7 (50%)
1 (7%)
1816±569
18.8±9.6

7 (58%)
4 (33%)
1 (8%)
1665±543
15.7±7.3

0.407
0.725
0.175

29.5±4.3

32.4±6.9

0.408

2 (14%)
5 (36%)
7 (50%)
10 (71%)
8.8±5.8

2 (17%)
4 (33%)
6 (50%)
8 (67%)
11.3±5.7

0.999

9 (64%)
5 (36%)

10 (83%)
2 (17%)

0.595

6 (43%)
2 (14%)
1 (7%)
1 (7%)
71 [60-88]

3 (25%)
3 (25%)
3 (25%)
1 (8%)
65 [60-83]

0.695
0.480
0.409
0.827
0.713

P
0.493

0.906
0.417

Table 3.2 Exercise prescription program variablesa
Low-Dose
High-Dose
∆ Between Groups
Characteristic
(n=14)
(n=12)
(LS Mean ± SE)
P
Frequency (days of exercise per week)
3.5±0.15
4.3±0.16
0.75±0.22
0.001
Fractionization (sessions of exercise per
1.1±0.07
1.4±0.07
0.31±0.10
0.001
day)
Intensity (% of heart rate maximum)
71.6±1.16
69.6±1.27
-1.89±1.72
0.272
Time (minutes of exercise per day)
41.6±2.38
59.1±2.57
17.4±3.50
<0.001
Type (% of exercise sessions using
72.3±12.9
81.3±15.5
8.0±18.71
0.669
treadmill)
Volume (minutes of exercise per week)
141.5±9.92
247.2±10.71
105.7±14.60
<0.001
4 [4-5]
8 [7-10]
4 [2-6]
0.007
Progression (weeks to full dose of
b
exercise)
% of exercise confirmed with HRM
97.3±0.81
96.2±0.87
-1.1±1.19
0.344
% adherence to prescribed exercise
92.8±2.44
89.0±2.64
-3.8±3.60
0.287
dose
% with ≥80% adherence, n (%)
12 (86%)
9 (75%)
-10.6±15.2
0.488
MET hours per weekc
13.7±0.96
23.9±1.03
10.2±1.41
<0.001
a
Data are least squares mean (LS Mean) ± standard error (SE) unless otherwise noted. bMedian
[interquartile 25-75% range]. cCalculated using available treadmill speed and incline, and averaged across
all exercise sessions.
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Table 3.3 Body composition outcomes at baseline and change during six months
Outcome
Body Mass, kg
Control
Low-Dose
High-Dose
Test for trend
BMI, kg/m2
Control
Low-Dose
High-Dose
Test for trend
Waist Circumference, cm
Control
Low-Dose
High-Dose
Test for trend
Hip Circumference, cm
Control
Low-Dose
High-Dose
Test for trend
Waist to Hip Ratio
Control
Low-Dose
High-Dose
Test for trend
Sagittal Abdominal Diameter, cm
Control
Low-Dose
High-Dose
Test for trend
Visceral Adipose Tissue, cm2
Control
Low-Dose
High-Dose
Test for trend
Subcutaneous Adipose Tissue,
cm2
Control
Low-Dose
High-Dose
Test for trend
Fat Mass, kg
Control
Low-Dose
High-Dose
Test for trend
Lean Mass, kg
Control
Low-Dose
High-Dose
Test for trend
Bone Mineral Density, g/cm2
Control
Low-Dose
High-Dose
Test for trend

Baseline
(Mean ± SD)

∆ Baseline to Month 6
(LS Mean ± SE)

∆ from Control
(LS Mean ± SE)

83.7±22.1
86.2±13.1
92.2±24.3

0.43±0.61
−0.51±0.57
−0.32±0.62
P=0.280

—
−0.95±0.84
−0.76±0.87

29.2±6.0
29.5±4.3
32.5±6.9

0.14±0.22
−0.17±0.21
−0.11±0.23
P=0.354

—
−0.31±0.30
−0.25±0.32

98.0±17.1
98.7±11.9
106.9±14.6

1.62±0.94
0.16±0.89
a
−2.90±0.96
P<0.001

—
−1.46±1.29
−4.52±1.34b

103.4±13.5
104.5±10.3
110.6±15.0

1.85±1.42
0.18±1.34
0.02±1.45
P=0.518

—
−1.67±1.95
−1.84±2.03

0.94±0.09
0.94±0.07
0.97±0.09

−0.005±0.011
0.001±0.011
a
−0.029±0.012
P=0.054

—
0.005±0.016
−0.023±0.016

22.6±4.0
22.4±3.6
23.9±4.0

0.45±0.32
0.01±0.30
0.01±0.32
P=0.200

—
−0.43±0.44
−0.45±0.46

112.6±55.2
131.3±45.6
154.2±60.5

5.31±4.80
−4.13±4.53
−8.27±4.89
P=0.008

—
−9.45±6.60
b
−13.58±6.86

388.4±142.6
381.1±138.6
461.9±110.9

−3.87±8.64
1.70±8.15
−17.86±8.81a
P=0.222

—
5.57±11.88
−14.00±12.34

32.8±10.0
32.6±7.6
38.1±11.9

−0.01±0.49
−0.13±0.47
−0.71±0.50
P=0.238

—
−0.12±0.68
−0.70±0.71

49.9±13.1
52.6±11.1
53.4±13.8

0.30±0.35
−0.06±0.33
0.01±0.36
P=0.450

—
−0.36±0.48
−0.29±0.50

1.08±0.10
1.03±0.12
1.02±0.09

0.006±0.005
0.021±0.005a
a
0.020±0.005
P=0.015

—
0.015±0.007b
0.013±0.007
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SD, standard deviation; LS Mean, least squares mean; SE, standard error. aSignifcantly different from
b
baseline (within-group), P≤0.05. Significantly different from control, P≤0.05.
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Figure 3.1 Flow of participants through the study
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Figure 3.2 Between group changes in A) visceral adipose tissue and B) waist
circumference from baseline to six months
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Abstract
Background: Physical activity is associated with a lower risk of disease recurrence
among colon cancer survivors. The pathways through which physical activity alters
disease outcomes are unknown, but may be mediated by changes in metabolic growth
factors, such as insulin.
Methods: Between January 2015 and August 2015, 39 stage I-III colon cancer survivors
were randomized to one of three groups: usual-care control, 150 min·wk-1 of aerobic
exercise (low-dose), and 300 min·wk-1 of aerobic exercise (high-dose) for six months.
The pre-specified key metabolic growth factor outcome was fasting insulin. Insulin
resistance was quantified using the homeostatic model assessment.
Results: Mean age was 56.5±10.0 years, 51% had stage III disease, 72% were treated
with chemotherapy, and the mean time since finishing treatment was 10.9±6.1 months.
Over six months, the low-dose group completed a mean 141.5±9.9 min·wk-1 of aerobic
exercise, and the high-dose group completed a mean 247.2±10.7 min·wk-1 of aerobic
exercise. Fasting insulin concentrations decreased 7.4±9.4 pmol/L in the control group,
28.0±8.3 pmol/L in the low-dose group, and 20.7±9.3 pmol/L in the high-dose group
(nonlinear Ptrend=0.042). Insulin resistance decreased 0.11±0.20 in the control group,
0.63±0.17 in the low-dose group, and 0.43±0.19 in the high-dose group (nonlinear
Ptrend=0.012).
Discussion: Aerobic exercise reduces insulin concentrations and insulin resistance
among patients with stage I-III colon cancer. Prescribing 150 min·wk-1 of aerobic
exercise may be sufficient for reducing insulin concentrations and insulin resistance,
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which may partially mediate the relationship between physical activity and colon cancer
prognosis.

Introduction
Each year more than 103,000 people are diagnosed with colon cancer in the United
States [Siegel et al, 2015]. Approximately three-quarters of patients will be diagnosed
with disease that is localized to the primary site (stage I-II) or spread to regional lymph
nodes (stage III). Despite surgical resection, either alone or in combination with
adjuvant chemotherapy, five-year recurrence rates for patients with stage I, II, and III
colon cancer are 10%, 20%, and 30-50%, respectively [André et al, 2004, Clinical
Outcomes of Surgical Therapy Study Group, 2004, Quasar Collaborative Group, 2007].
Consequently, there exists a need to identify additional adjuvant therapies that reduce
the risk of recurrent disease in this population.
The prescription of physical activity or exercise is a potential adjuvant therapy that has
been reported in multiple observational studies to be associated with a reduction in the
risk of recurrence and death among colon cancer survivors [Campbell et al, 2013, Kuiper
et al, 2012, Meyerhardt et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009]. The
relationship between physical activity and disease outcomes is independent of known
prognostic factors, and occurs in a dose-response fashion, such that higher volumes of
physical activity or exercise, up to 300 minutes per week (min·wk-1), are associated with
more favorable disease outcomes [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt
et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009].
The biologic or biobehavioral pathways through which exercise may favorably alter colon
cancer outcomes have not been elucidated, but may include exercise-induced
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alterations in metabolic growth factors, such as insulin, C-peptide, insulin-like growth
factor-1 (IGF-1), and insulin-like growth factor-binding protein-3 (IGFBP-3). Colon
cancer cells have insulin/IGF-1 receptors on their surface [Belfiore and Malaguarnera,
2011] and insulin/IGF-1 promote colon cancer cell proliferation and inhibit apoptosis
[Koenuma et al, 1989]. In vitro studies demonstrate that states of hyperinsulinemia
increase colon cancer cell resistance to 5-fluorouracil [Chen et al, 2011b] and oxaliplatin
chemotherapy [Chen et al, 2011a, Volkova et al, 2014]. Preclinical models demonstrate
that exposure to insulin promotes colonic tumor multiplicity [Tran et al, 1996]. Elevated
levels of C-peptide and lower levels of IGFBP-3 are associated with a higher risk of
death among men and women with colon cancer [Haydon et al, 2006b, Wolpin et al,
2009]. Together, this evidence supports the hypothesis that insulin and IGF-1 may be
important mediators of the relationship between exercise and disease outcomes among
colon cancer survivors.
Colon cancer survivors have fasting insulin concentrations that are 58% higher than
healthy controls without a history of colon cancer [Jiang et al, 2014]. A pilot study of 17
colon cancer survivors demonstrated that a three-month prescription of exercise reduced
insulin and increased IGF-1 and IGFBP-3 concentrations [Lee et al, 2013]. However, no
randomized trials have examined the dose-response effects of exercise on metabolic
growth factors among colon cancer survivors.
These observations provided the scientific rationale for the COURAGE trial, a randomized
controlled trial investigating the safety, feasibility, and biological efficacy of 150 and 300
min·wk-1 of aerobic exercise versus usual care control over six months among men and
women recently-treated for stage I-III colon cancer [Brown et al, 2016]. Here we report
on fasting insulin as the pre-specified key metabolic growth factor of interest. We have
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previously demonstrated that visceral adipose tissue is reduced with exercise [Brown et
al, to be submitted]. As an exploratory aim of this report, we characterized the
relationship between changes in visceral adipose tissue with changes in fasting insulin.
Our hypotheses were that: 1) exercise would reduce fasting insulin concentrations in a
dose-response fashion; and 2) reductions in visceral adipose tissue would correlate with
reductions in fasting insulin.

Methods
Participants
Study methods of the COURAGE trial were published [Brown et al, 2016]. Participants
were recruited from the metropolitan Philadelphia region and surrounding counties.
Participants were eligible if they: 1) were diagnosed with histologically-proven stage I-III
colon cancer; 2) completed surgical resection and adjuvant chemotherapy within 36
months of entering the study; 3) self-reported participating in ≤150 min·wk-1 of moderate
or vigorous intensity physical activity using the Paffenbarger Physical Activity
Questionnaire [20]; 4) were of age ≥18 years; 5) provided written physician approval; 6)
had no additional surgery planned within the six month intervention period (including
colostomy reversal); and 7) had the ability to walk unassisted for six-minutes.
Participants were ineligible if they: 1) had a history of another primary cancer (other than
non-melanoma skin-cancer); 2) had evidence of metastatic cancer; 3) were pregnant or
breast feeding; 4) were unable to provide a baseline blood sample; 5) had a myocardial
infarction or coronary revascularization procedure within the past three months; 6) had
uncontrolled hypertension, defined as a systolic blood pressure ≥180 mm Hg or diastolic
blood pressure ≥100 mm Hg; 7) had high-risk or uncontrolled heart arrhythmias (not
including atrial fibrillation); 8) had clinically significant heart valve disease; 9) had
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decompensated heart failure; 10) had a known aortic aneurysm; or 11) had any other
condition which, in the opinion of the investigator, may impede testing of the study
hypothesis or make it unsafe to engage in the exercise program.
Participants were stratified by cancer stage (AJCC 7th Edition: I vs II vs III) and
randomized into one of three groups: low-dose aerobic exercise (150 min·wk-1), highdose aerobic exercise (300 min·wk-1), or usual care control. This study was approved by
the University of Pennsylvania Institutional Review Board. All participants provided
written informed consent and written approval from their physician prior to participation in
any study-related activities.
Intervention
Participants randomized to the low-dose or high-dose exercise groups were provided
with an in-home treadmill (LifeSpan Fitness, TR1200i, Salt Lake City, UT) to promote
exercise adherence, and a heart rate monitor (Polar Electro, RS400, Kempele Finland)
to objectively record exercise intensity and duration. Participants also documented their
exercise in a written log book. Exercise intensity was prescribed at 50-70% of the agepredicted maximum heart rate (3-6 METs [Ainsworth et al, 2000]). The low-dose and
high-dose groups progressed towards of the goal of 150 or 300 min·wk-1 of exercise,
respectively. Participants met with a certified clinical exercise physiologist to introduce
the exercise prescription, and familiarize the participant with use of the treadmill,
completion of exercise logs, use of a heart rate monitor, appropriate warm-up and cooldown, stretches, and proper footwear for aerobic exercise. Participants were
encouraged to individualize their frequency (days per week), fractionation (sessions per
day), and duration (minutes per day) of exercise according to a schedule that promoted
a high level of adherence to the prescribed exercise volume. The exercise physiologist
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provided ongoing behavioral and clinical support and monitored exercise adherence to
the study protocol throughout the duration of the study. Detailed methods of the
exercise intervention were published [Brown et al, 2016].
Participants randomized to the usual-care control group were asked to maintain their
pre-study levels of physical activity or follow the recommendations provided by their
physician. After completing six month measures, control group participants were
provided with an in-home treadmill and individualized exercise program, similar to that
prescribed to the two exercise groups. Upon completion of study-related activities, all
participants were allowed to keep their study-provided treadmills.
Measurements
Baseline and follow-up measurements were obtained by trained staff members who
were blinded to treatment assignment. Demographic characteristics including age, sex,
race, and education were self-reported. Smoking status was obtained from a
standardized questionnaire [Pleis et al, 2009]. Daily caloric intake and the proportion of
calories from carbohydrate sources were quantified using three-day food records that
were analyzed using the Nutrition Data System for Research software (v.2014) by a
registered dietitian who was blinded to study group. Moderate to vigorous intensity
physical activity was quantified using an accelerometer (ActiGraph GT3X+) with cutpoints appropriate for adults [Troiano et al, 2008]. Clinical information including cancer
stage, treatment with chemotherapy, and performance status were obtained from the
Pennsylvania State Cancer Registry, pathology reports, and physician records. Fiveyear predicted overall survival was calculated using a validated prognostic model for
colon cancer [Weiser et al, 2011]. Body mass index (BMI; kg/m2) was calculated using
standard anthropometric measures [weight (kg) and height (m)], and dual-energy x-ray
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absorptiometry was used to quantify visceral adipose tissue, as previously described
[Brown et al, 2016].
Metabolic Growth Factor Outcomes
All study participants underwent a fasting blood draw at baseline and follow-up. EDTApreserved plasma was stored at −80°C. Insulin and C-peptide concentrations were
quantified using a radioimmunoassay (EMD Millipore, Billerica, MA). IGF-1, IGFBP-3,
and fructosamine concentrations were quantified using an enzyme-linked
immunosorbent assay (DSL, Webster, TX). Glucose concentrations were quantified
spectrophotometrically (Roche, Indianapolis, IN). Baseline and follow-up plasma
samples were assayed simultaneously and in duplicate at the end of the study.
Coefficients of variation for all samples were ≤10%. The homeostatic model assessment
(HOMA) was used to quantify insulin resistance [Levy et al, 1998].
Statistical Analysis
Descriptive statistics presented for baseline variables include counts and proportions for
categorical variables and means ± standard deviations for continuous variables.
Categorical baseline characteristics were compared among the three groups using
Fisher’s exact test, and continuous baseline characteristics were compared among the
three study groups using the Kruskal-Wallis test. Based on prior research [Houmard et
al, 2004], we estimated a mean change in fasting insulin concentrations of +6.6 pmol/L
in the control group, −3.3 pmol/L in the low-dose group, and −5.9 pmol/L in the highdose group with a pooled standard deviation of ±4.6 pmol/L over six months. Against
the hypothesis of a dose-response relationship, 39 participants provided 80% power with
a type I error rate of 5% (α=0.05). All inferential analyses were conducted on an
intention-to-treat basis. Dependent variables were log transformed in the inferential
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analysis to improve normality and back transformed to facilitate interpretation. Changes
were evaluated from baseline to follow-up in the three groups using repeated-measures
mixed-effects regression models. This statistical approach includes all available data
and accounts for the correlation between repeated measures. The baseline value of the
dependent variable and cancer stage (randomization stratification factor) were included
as covariates in the regression models [Fitzmaurice et al, 2004]. Group-by-time
interaction terms were included as fixed-effects in the regression model. Results from
the repeated-measures mixed-effects regression models are presented as least-square
means ± standard error. To evaluate the presence of a dose-response relationship
across randomized groups, a test of trend was conducted by examining linear and
nonlinear (quadratic) contrasts. Linear regression models were used to characterize
changes in visceral adipose tissue with changes in growth factor concentrations from
baseline to six months. All statistical analyses were completed using Stata/MP Version
14.1 (StataCorp, College Station, TX).

Results
Between January 2015 and August 2015, 39 colon cancer survivors were recruited and
randomized with data collection ending in February 2016. Baseline characteristics of
study participants are presented in Table 4.1. Age ranged from 35–81 years. BMI
ranged from 20–43 kg/m2; 31% of participants were overweight (BMI 25.0–29.9 kg/m2)
and 51% were obese (BMI≥30 kg/m2). Time since finishing colon cancer treatment
ranged from 1–21 months. Five-year predicted overall survival ranged from 35–92%.
Five participants had type 2 diabetes mellitus at baseline, all were diagnosed ≥3 years
prior to study enrollment, and all were using metformin (one as monotherapy, four as
combination therapy with a sulfonylurea or DPP-4 inhibitor). Figure 4.1 shows the flow
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of the 39 randomized participants through the study. One participant was lost to followup.
Exercise prescription program variables are presented in Table 4.2. Over six months,
the average exercise volumes in the low-dose and high-dose groups were 141.5±9.92
min·wk-1 (92.8±2.44% of prescribed dose) and 247.2±10.71 min·wk-1 (89.0±2.64% of
prescribed dose), respectively. The high-dose group completed on average an
additional 105.7±14.60 min·wk-1 of exercise than the low-dose group (P<0.001).
Exercise intensity was 70.7±0.85% of the age-predicted maximal heart rate and did not
differ between groups (P=0.272). The proportion of exercise sessions validated with
objective heart rate data was 96.8±0.59% and did not differ between groups (P=0.344).
Accelerometer-quantified moderate to vigorous intensity physical activity increased in
dose-response fashion (linear Ptrend<0.001); over six months the control group increased
by 4.2±6.5 min·d-1, whereas the low-dose and high-dose groups increased by 26.5±6.1
and 33.1±6.5 min·d-1, respectively. Daily caloric intake and the proportion of daily
calories from carbohydrate sources were not significantly different from baseline in any
of the groups (data not shown).
Metabolic growth factor concentrations are presented in Table 4.3. At baseline, no
differences were observed among the three groups. Fasting insulin concentration, the
key growth factor outcome, decreased 7.4±9.4 pmol/L in the control group, 28.0±8.3
pmol/L in the low-dose group, and 20.7±9.3 pmol/L in the high-dose group (nonlinear
Ptrend=0.042; Figure 4.2). Similarly, insulin resistance decreased 0.11±0.20 in the
control group, 0.63±0.17 in the low-dose group, and 0.43±0.19 in the high-dose group
(nonlinear Ptrend=0.012). Fasting glucose concentration decreased in the low-dose
group, whereas no difference was observed high-dose and control groups (nonlinear
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Ptrend=0.004). IGF-1, IGFBP-3, fructosamine, and C-peptide did not change in any of the
study groups. Adjustment for type 2 diabetes mellitus as a covariate in the regression
models did not substantively alter the above-described findings. No serious (grade ≥3)
adverse events occurred.
As we have previously reported, exercise reduced visceral adipose tissue in a doseresponse fashion (linear Ptrend=0.008), such that each 60 min·wk-1 increase in exercise
volume predicted a –2.7±1.4 cm2 reduction in visceral adipose tissue [Brown et al]. For
each 1 cm2 reduction in visceral adipose tissue, fasting insulin concentration was
lowered by 0.96±0.41 pmol/L (P=0.025; Table 4.4, Figure 4.3) and changes in visceral
adipose tissue accounted for 13.5% of the shared variance in changes in fasting insulin
concentrations. Changes in visceral adipose tissue also correlated with changes in
fasting glucose and insulin resistance.

Discussion
A six month moderate-intensity aerobic exercise program among stage I-III colon cancer
survivors reduced fasting insulin concentrations and insulin resistance in a
predominately overweight and obese population. The findings from this randomized trial
support the hypothesis that the relationship between physical activity and colon cancer
prognosis may be mediated, in part, by changes in fasting insulin concentrations or
insulin resistance.
The reductions in fasting insulin concentrations and insulin resistance with exercise are
similar to those observed in a prior dose-response study in overweight and obese adults
[Ross et al, 2015]. This study indicated that fasting insulin concentrations and insulin
resistance may be lowered uniformly across distinct exercise doses in an L-shaped
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pattern [Ross et al, 2015]. The absolute magnitude of reduction in fasting insulin
concentrations in the current study was larger compared to other studies [Houmard et al,
2004, Ross et al, 2015]. This may be the result of our sample having higher baseline
fasting insulin concentrations (111 pmol/L vs 49 pmol/L [Houmard et al, 2004] and 67.5
pmol/L [Ross et al, 2015]), which is consistent with a prior report that colon cancer
survivors have significantly higher fasting insulin concentrations than matched healthy
controls [Jiang et al, 2014]. Our findings are consistent with studies in breast cancer
survivors that exercise reduces fasting insulin concentrations [Irwin et al, 2009, Ligibel et
al, 2008].
In cross-sectional analyses, fasting insulin concentrations are higher with larger volumes
of visceral adipose tissue, an effect that is attributable to increased insulin resistance
[Goodpaster et al, 2003]. We demonstrated that changes in visceral adipose tissue
account for only 13.5% of the shared variance in insulin concentration, consistent with a
prior study in obese men that estimated the shared variance to be 22% [Rice et al,
1999]. These data suggest that the effects of exercise to lower fasting insulin may
include mechanisms beyond that of changes in visceral adipose tissue. We hypothesize
that alterations in skeletal muscle insulin resistance and free fatty acid (FFA) metabolism
may help to further explain this effect [Abdul-Ghani and DeFronzo, 2010, DeFronzo and
Tripathy, 2009]. Insulin resistance in skeletal muscle is associated with
hyperinsulinemia [Abdul-Ghani and DeFronzo, 2010, DeFronzo and Tripathy, 2009], and
the inability to lower FFA in the postprandial state [Jensen, 2008]. Skeletal muscle
preferentially oxidizes FFA [Randle et al, 1963], suppressing insulin-stimulated glucose
uptake into the muscle [Boden et al, 1994, Dresner et al, 1999]. Exercise improves the
insulin suppression of FFA release [Shadid and Jensen, 2006], corrects the mismatch
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between FFA uptake and FFA oxidation [Turcotte and Fisher, 2008], and promotes
insulin-stimulated glucose uptake into skeletal muscle [Hayashi et al, 1997].
The biologic or biobehavioral pathways through which exercise may alter disease
outcomes are unknown. States of hyperinsulinemia activate the PI3K-Akt-mTOR
pathway [McCurdy and Klemm, 2013]. In preclinical experiments, activation of the PI3KAkt-mTOR pathway promotes the growth of colon cancer metastases [Gulhati et al,
2011], and inhibition of this pathway induces cell-cycle arrest and apoptosis [Zhang et al,
2009]. Insulin receptor substrate 1 (IRS1) is a mediator of glucose homeostasis, and
the down regulation of IRS1 is associated with insulin resistance [Karlsson and Zierath,
2007]. Tumor expression of IRS1 and physical activity interact to influence colon cancer
outcomes [Hanyuda et al, 2015]. Among patients with decreased expression of IRS1,
physical activity is associated with a significant reduction in the risk of colon cancerspecific mortality (Ptrend=0.005) whereas no relationship was observed with IRS2. IRS1
is associated with insulin metabolism in skeletal muscle, whereas IRS2 is associated
with insulin metabolism in the liver [Karlsson and Zierath, 2007]. These observational
data provide additional data to support the hypothesis that exercise may have an insulin
sensitizing effect that is produced through skeletal muscle contractions, and this insulin
sensitization may influence disease outcomes.
There are several limitations to this trial. The main limitation is the small size of the
study sample which limits the generalizability of our findings. We have previously
demonstrated that participants in this trial were younger than the population from which
they were recruited [Brown et al, 2016]. The small sample size precluded our ability to
undertake formal mediation analysis to explore the relationships among exercise dose,
insulin concentrations, and visceral adipose tissue [Friedenreich et al, 2011]. The small
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sample size also limited our statistical power to examine other metabolic growth factors
such as IGF-1. Our study was only six months in duration. It is unknown if the observed
improvements in outcomes would be sustained or improved upon over a longer time
horizon. Participants were not recruited on the basis of having hyperinsulinemia;
however 82% of our study sample was overweight or obese, consequently
hyperinsulinemia was common. We examined two distinct volumes of moderateintensity aerobic exercise, but we did not examine the effects of low-intensity aerobic
exercise.
There are several strengths to this trial. The use of two intervention groups, each
prescribed a distinct dose of exercise allowed us to examine changes in fasting insulin
along the exercise dose curve. The exercise program, which emphasized home-based
treadmill walking, promoted good intervention adherence that was confirmed with
objective heart rate monitor measures. The majority of participants (97%) completed the
study.
In summary, the findings from this randomized dose-response trial demonstrate that
moderate-intensity aerobic exercise reduces fasting insulin concentrations and insulin
resistance among patients who have recently completed treatment for stage I-III colon
cancer. The findings from this randomized trial may be useful to help guide exercise
prescriptions in this population. The relationship between physical activity and colon
cancer prognosis may be mediated, in part, by changes in insulin concentrations or
insulin resistance. Continued research to examine this hypothesis is warranted.
Disclosure Statement

91

The authors declare no conflicts of interest. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the National
Institutes of Health.
Acknowledgements
This research was supported by R21-CA182767, F31-CA192560 and U54-CA155850
from the National Cancer Institute, P30-DK019525 from the National Institute of
Diabetes and Digestive and Kidney Diseases, and UL1-TR000003 from the National
Center for Research Resources and the National Center for Advancing Translation
Science. This research was supported by discounts for treadmills from LifeSpan
Fitness, LLC (Salt Lake City, UT). We thank the Pennsylvania Cancer Registry for their
role in recruitment activities for this study. We thank Dr. Heather Collins of the
University of Pennsylvania Diabetes Research Center for conducting the assays used to
quantify metabolic growth factor outcomes.

92

Table 4.1 Baseline characteristics of the participants
Total
Characteristic
(n=39)
Age, years
56.5±10.0
Sex, %
Male
15 (38%)
Female
24 (62%)
Race, %
White
31 (80%)
Black
6 (15%)
Other
2 (5%)
Education, %
High School or Less
7 (18%)
Some College
8 (20%)
College Degree or More
24 (62%)
Smoking History, %
Never
23 (59%)
Former
14 (36%)
Current
2 (5%)
-1
1747±542
Caloric Consumption, kcal·d
Calories from Carbohydrate, %
45.6±8.8
Moderate or Vigorous Physical
15.7±8.7
-1
Activity, min·d
Body Mass Index, kg·m-2
30.3±5.8
Stage, %
I
5 (13%)
II
14 (36%)
III
20 (51%)
Chemotherapy, %
28 (72%)
Time Since Treatment Completion,
10.9±6.1
Months
ECOG Performance Status, %
0, Fully active
29 (74%)
1, Ambulatory, but restricted in
10 (26%)
strenuous activity
Comorbid Conditions, %
Hypertension
13 (33%)
Hyperlipidemia
6 (15%)
Type 2 Diabetes
5 (13%)
Cardiovascular Disease
4 (10%)
5-Year Predicted Survival, %
68 [60-87]
P values are from the overall test of group differences.
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Control
(n=13)
57.9±9.7

Low-Dose
(n=14)
58.2±9.8

High-Dose
(n=12)
53.1±10.5

4 (31%)
9 (69%)

7 (50%)
7 (50%)

4 (33%)
8 (67%)

0.601

8 (62%)
3 (23%)
2 (15%)

12 (86%)
2 (14%)
0 (0%)

11 (92%)
1 (8%)
0 (0%)

0.332

1 (8%)
3 (23%)
9 (69%)

4 (29%)
2 (14%)
8 (57%)

2 (17%)
3 (25%)
7 (58%)

0.765

10 (77%)
3 (23%)
0 (0%)
1749±545
45.0±10.6
12.2±8.1

6 (43%)
7 (50%)
1 (7%)
1816±569
46.6±7.3
18.8±9.6

7 (58%)
4 (33%)
1 (8%)
1665±543
45.2±9.2
15.7±7.3

0.407
0.725
0.701
0.175

29.2±6.0

29.5±4.3

32.4±6.9

0.408

1 (8%)
5 (38%)
7 (54%)
10 (77%)
11.3±6.7

2 (14%)
5 (36%)
7 (50%)
10 (71%)
8.8±5.8

2 (17%)
4 (33%)
6 (50%)
8 (67%)
11.3±5.7

0.999

10 (77%)
3 (23%)

9 (64%)
5 (36%)

10 (83%)
2 (17%)

0.595

4 (31%)
1 (8%)
1 (8%)
2 (15%)
68 [61-85]

6 (43%)
2 (14%)
1 (7%)
1 (7%)
71 [60-88]

3 (25%)
3 (25%)
3 (25%)
1 (8%)
65 [60-83]

0.695
0.480
0.409
0.827
0.713

P
0.493

0.906
0.417

Table 4.2 Exercise prescription program variablesa
Low-Dose
High-Dose
∆ Between Groups
Characteristic
(n=14)
(n=12)
(LS Mean ± SE)
P
Frequency (days of exercise per week)
3.5±0.15
4.3±0.16
0.75±0.22
0.001
Fractionization (sessions of exercise per
1.1±0.07
1.4±0.07
0.31±0.10
0.001
day)
Intensity (% of heart rate maximum)
71.6±1.16
69.6±1.27
-1.89±1.72
0.272
Time (minutes of exercise per day)
41.6±2.38
59.1±2.57
17.4±3.50
<0.001
Type (% of exercise sessions using
72.3±12.9
81.3±15.5
8.0±18.71
0.669
treadmill)
Volume (minutes of exercise per week)
141.5±9.92
247.2±10.71
105.7±14.60
<0.001
4 [4-5]
8 [7-10]
4 [2-6]
0.007
Progression (weeks to full dose of
b
exercise)
% of exercise confirmed with HRM
97.3±0.81
96.2±0.87
-1.1±1.19
0.344
% adherence to prescribed exercise
92.8±2.44
89.0±2.64
-3.8±3.60
0.287
dose
% with ≥80% adherence, n (%)
12 (86%)
9 (75%)
-10.6±15.2
0.488
MET hours per weekc
13.7±0.96
23.9±1.03
10.2±1.41
<0.001
a
Data are least squares mean (LS Mean) ± standard error (SE) unless otherwise noted. bMedian
[interquartile 25-75% range]. cCalculated using available treadmill speed and incline, and averaged across
all exercise sessions.
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Table 4.3 Metabolic growth factor outcomes at baseline and change during six months
Outcome
Insulin, pmol/L
Control
Low-Dose
High-Dose
Test for trend

Baseline
(Mean ± SD)

∆ Baseline to Month 6
(LS Mean ± SE)

∆ from Control
(LS Mean ± SE)

99.2±60.5
101.8±40.5
135.1±87.1

−7.36±9.41
a
−28.02±8.35
−20.70±9.35a
Linear, P=0.170
Nonlinear, P=0.042

—
−20.66±12.58
−13.34±13.26

5.3±1.0
5.3±0.8
6.1±2.3

0.01±0.16
a
−0.39±0.15
−0.09±0.17
Linear, P=0.931
Nonlinear, P=0.004

—
−0.39±0.22
−0.09±0.24

2.2±1.3
2.2±0.9
2.9±2.0

−0.11±0.20
a
−0.63±0.17
a
−0.43±0.19
Linear, P=0.125
Nonlinear, P=0.012

—
−0.52±0.26b
−0.32±0.27

IGF-1, nmol/L
Control
Low-Dose
High-Dose
Test for trend

58.0±15.9
59.8±13.2
64.7±17.5

−4.57±3.23
−0.94±3.21
1.62±3.57
Linear, P=0.054
Nonlinear, P=0.850

—
3.63±4.55
6.19±4.82

IGFBP-3, nmol/L
Control
Low-Dose
High-Dose
Test for trend

1765.1±446.8
1925.7±449.5
2290.0±748.2

−103.71±69.15
−30.01±68.04
−154.28±71.97a
Linear, P=0.685
Nonlinear, P=0.093

—
73.69±97.27
−50.58±100.13

C-Peptide, nmol/L
Control
Low-Dose
High-Dose
Test for trend

0.64±0.4
0.58±0.3
0.75±0.3

0.007±0.033
−0.003±0.032
−0.013±0.035
Linear, P=0.701
Nonlinear, P=0.934

—
−0.010±0.046
−0.020±0.048

Glucose, mmol/L
Control
Low-Dose
High-Dose
Test for trend
Insulin Resistance
(HOMA)
Control
Low-Dose
High-Dose
Test for trend

Fructosamine, mmol/L
Control
Low-Dose
High-Dose
Test for trend

201.4±20.5
183.0±51.2
204.1±28.6

2.60±16.82
—
22.91±15.84
20.31±23.11
−12.65±16.96
−15.26±23.89
Linear, P=0.380
Nonlinear, P=0.382
SD, standard deviation; LS Mean, least squares mean; SE, standard error; HOMA, homeostatic model
a
b
assessment. Signifcantly different from baseline (within-group), P≤0.05. Significantly different from control,
P≤0.05.
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Table 4.4 Relationship between change in visceral adipose
tissue (per 1 cm2 reduction) and change in metabolic growth
factor concentration during six months
∆ in Metabolic Growth
Factor Concentration
(LS Mean ± SE)
−0.96±0.41
−0.03±0.01
−0.024±0.009

Outcome
R2
P
Insulin, pmol/L
13.5%
0.025
Glucose, mmol/L
21.9%
0.004
Insulin Resistance
16.5%
0.013
(HOMA)
IGF-1, nmol/L
−0.22±0.13
7.6%
0.098
IGFBP-3, nmol/L
−1.22±3.16
0.4%
0.701
C-Peptide, mmol/L
0.0007±0.001
0.6%
0.650
Fructosamine, mmol/L
−0.16±0.47
0.3%
0.736
LS Mean, least squares mean; SE, standard error; R2, proportion of variability
of change in metabolic growth factor concentration explained by change in
visceral adipose tissue.

96

Figure 4.1 Flow of participants through the study
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Figure 4.2 Between group changes in fasting insulin concentration from baseline to six
months
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Figure 4.3 Relationship between changes in visceral adipose tissue area and changes
in fasting insulin concentration from baseline to six months
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CHAPTER 5. CONCLUSIONS & FUTURE DIRECTIONS
The purpose of this dissertation was to clarify how exercise may alter pathways that are
hypothesized to influence disease outcomes among colon cancer survivors. We also
examined the generalizability of our study population to the broader population of colon
cancer survivors. The data gathered from this dissertation help to improve the specificity
of exercise prescriptions provided to colon cancer survivors, strengthen the rationale that
a causal relationship exists between exercise and disease outcomes, and refine key
design aspects for future randomized trials in this population.
Specific aim one sought to quantify and describe the dose-response effects of moderateintensity aerobic exercise on visceral adipose tissue (VAT). We hypothesized that
exercise would favorably reduce VAT in dose-response fashion. Our hypothesis was
supported as moderate-intensity aerobic exercise significantly reduced VAT in linear
dose-response fashion (Ptrend=0.008). Specific aim two sought to quantify and describe
the dose-response effects of moderate-intensity aerobic exercise on levels of fasting
insulin. We hypothesized that exercise would favorably reduce levels of fasting insulin in
dose-response fashion. Our hypothesis was supported as moderate-intensity aerobic
exercise significantly reduced levels of fasting insulin in nonlinear fashion (Ptrend=0.042).
Specific aim three sought to quantify and describe demographic, clinical, and
geographical characteristics associated with eligibility screening and study enrollment.
We hypothesized that demographic, clinical, and geographical characteristics would be
associated with eligibility screening and study enrollment. Our hypothesis was
supported as colon cancer survivors who were screened for eligibility and enrolled in the
study were significantly younger (screening P<0.001, enrollment P=0.007) and more
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likely to have been treated with chemotherapy (screening P<0.001, enrollment P=0.006)
than the population from which they were recruited.
Since the initiation of the COURAGE trial, research has continued to accumulate that
further strengthens the rationale and scientific basis for this line of inquiry.
Epidemiologic data have provided additional evidence supporting the association
between physical activity and disease outcomes among colon cancer survivors
[Campbell et al, 2013] and these data have now been summarized in systematic reviews
and meta-analyses that demonstrate a dose-response relationship between physical
activity and outcomes [Je et al, 2013, Schmid and Leitzmann, 2014]. Molecular
epidemiology studies have characterized tumor features that help to identify patients
who may reap the largest cancer-specific benefits from exercise [Hanyuda et al, 2015,
Yamauchi et al, 2013]. Preclinical models have provided important mechanistic data to
guide clinical studies [Huffman et al, 2013]. Evidence continues to emerge that VAT and
hyperinsulinemia are associated with disease recurrence and mortality among colon
cancer survivors [Cakir et al, 2015, Devin et al, 2015].
Understanding how the dose of physical activity influences cancer prognosis is one of
the most provocative unanswered questions in oncology [Lam et al, 2013]. The National
Cancer Institute has expanded its funding portfolio to support research to answer this
question [Alfano et al, 2016, Ballard-Barbash et al, 2013]. Elucidating if and how
physical activity reduces the risk for cancer recurrence and/or improves survival is
currently the #1 research question in the field of exercise-oncology [Courneya et al,
2015]. The importance of this line of research has been echoed by various national
organizations including the Institute of Medicine (IOM), American Society of Clinical
Oncology (ASCO), American Association of Cancer Research (AACR), American
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Society of Preventive Oncology (ASPO), and the American Cancer Society (ACS), as all
of these organizations have hosted meetings with themes focused on energy balance,
exercise, obesity, and lifestyle practices to promote healthy cancer survivorship. Some
organizations have published position papers from these meetings [Alfano et al, 2014,
Demark-Wahnefried et al, 2012, Ligibel et al, 2014, Ligibel et al, 2015]. Given the recent
surge of enthusiasm in this area, the findings from the COURAGE trial are timely, are of
high interest to the clinical and research communities, and will provide important data to
guide the field over the next decade.
As described in Chapter 1, oncologists will continue to field questions such as “Should I
exercise? Should I lose weight? What will improve my chances?” from the 83,000
people who are diagnosed with non-metastatic colon cancer each year. Oncology
providers are uniquely positioned to offer guidance about exercise to patients. Patients
often view oncologists as decision-makers for their health, and the oncologist
recommendation is possibly the biggest catalyst to initiate behavior change [Brown and
Schmitz, 2014a]. Patients are likely to remember recommendations about physical
activity from their oncologist if there is the perception that the provider values such
behaviors. A diagnosis of cancer is often viewed as a teachable moment where patients
may be amenable to adopting recommendations about physical activity and other
lifestyle behaviors, such as quitting smoking, losing weight, and improving their diet
[Brown and Schmitz, 2014a]. Clinical practice guidelines encourage oncology providers
to recommend that patients engage in a physically active lifestyle [Meyerhardt et al,
2013]. After making this recommendation to patients, providers often field the follow-up
question of “How much should I do?” or “How much is enough?” The data generated
from this dissertation begins to answer these questions. The linear dose-response
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reductions observed for VAT, and the nonlinear dose-response reductions observed for
fasting insulin suggest that providers should encourage patients work towards the goal
of 300 min·wk-1 as long as the provider believes it is safe to do so. This
recommendation is also grounded in behavioral science practices, wherein higher
exercise goals result in more exercise completed, even if the goals themselves are not
achieved [Hultquist et al, 2005, Perri et al, 2002].
These data are useful to begin to fill the developmental pipeline for binging exercise to
the standard of clinical care for adjuvant colon cancer (see Figure 1.6 in Chapter 1).
Recruitment, adherence, and follow-up are three critical aspects to success for any trial,
particularly a behavioral trial such as COURAGE. Perhaps the most novel feature of this
trial was the provision of permanent in-home treadmills. The purpose of providing inhome treadmills was three-fold. First, it served as a reasonable incentive for
participation. This effort was successful as recruitment was completed ahead of
schedule. Second, it was provided to promote high levels of exercise adherence. This
effort was successful as exercise adherence in the low-dose and high-dose groups were
92% and 89%, respectfully. The provision of a treadmill was cited by nearly every
participant as being central to their exercise success and motivation to meet the study
goals. For example: “I feel blessed for that treadmill in my living room, I wouldn’t be this
good with my exercise if I had to go outside all the time” [participant 025 in the low-dose
group quoted at month 5 of the study. This participant finished with 100% adherence]
and “I feel like you have positioned me for lifelong success with this treadmill, knowing
that you invested this much in me provided the motivation to do my exercise on the days
I was feeling sluggish” [participant 016 in the high-dose group quoted at the end of the
study. This participant finished with 98% adherence]. Third, it provided an incentive for
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control group participants to successfully complete the study. This effort was successful
as 12 of 13 control group participants, and all 26 participants in the two exercise groups,
completed the trial (97% completion rate). Although it is possible to conduct trials of
exercise without providing in-home exercise equipment, the experience from this trial is
consistent with the hypothesis that the provision in-home exercise equipment may
improve recruitment, adherence, and follow-up. If the principal goal of prescribing
exercise to colon cancer survivors is to prevent disease recurrence, then an in-home
treadmill is similar to durable medical equipment. Future studies that provide in-home
exercise equipment should aim to quantify the cost-effectiveness of such an approach.
The treadmills provided in our study cost $1,000 per person. The cost of treating
recurrent colon cancer with palliative chemotherapy often exceeds $100,000 per person
per year [Wong et al, 2009]. Empirical data that integrate costs, patient satisfaction, and
the magnitude of health benefit will help to guide the development of interventions that
are designed to succeed from a patient, provider, and third-party payor perspective
when adopted into the standard of care for colon cancer.
This area is rich with opportunities to understand how exercise can be used to promote
healthy colon cancer survivorship. This dissertation contributes to advancing that
mission. Additional data from future trials are urgently needed. These additional data
will allow for more definitive guidance to colon cancer survivors. As described in
Chapter 1, future studies should build upon this work by investigating the specific
pathways through which exercise improves disease outcomes. The collaboration of
clinical and basic scientists will accelerate progress in this area [Gehlert et al, 2014].
Future single-center studies should continue to monitor the safety and feasibility of
exercise, while documenting the physiologic changes that are hypothesized to mediate
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the relationship between exercise and disease outcomes. In the near future, multicenter
feasibility trials will be necessary to increase sample sizes and commence a coordinated
effort to improve efficiency and concentrate synergy. The planning and design of these
multicenter feasibility trials are of critical importance given that their purpose will be to
establish a robust foundation on which to build definitive phase III trials.
In conclusion, we have demonstrated that exercise induces several favorable
physiologic changes among colon cancer survivors. Such changes include reductions in
VAT and reductions in fasting insulin concentration. The participants in this trial were
younger and more likely to have been treated with chemotherapy than the population
from which they were recruited. Disease recurrence is a formidable reality for many
colon cancer survivors and presents a critical barrier to long term survivorship.
Continued efforts to elucidate the biologic or biobehavioral pathways through which
exercise improves colon cancer outcomes are necessary. Generating the compendium
of evidence that is sufficiently persuasive to shift clinical practice will be complex, time
consuming, and undoubtedly encounter bumps in the process. However, the
satisfaction of empowering patients, families, and providers with practical evidencebased solutions to reduce the risk of disease recurrence is well worth the necessary
sacrifice.

###
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